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Objectives  
This study was done to establish a correlation between rotational thromboelastometryparameters 
and standard coagulation profile in the context of acquired bleeding disorders. 
Background 
Acquired bleeding disorders are a major cause of mortality, both in the developed and 
developing countries. An acute haemorrhage should be managed immediately with blood 
products, factor concentrates or antifibrinolytics. Investigations to detect coagulopathies 
typically include baseline screening tests like prothrombin time, activated partial thromboplastin 
time, platelet count and fibrinogen level. These tests have a long turnaround time which 
frequently lead to a blinded approach towards blood product support leading to under or over 
transfusion. In contrast, rotational thromboelastometry (ROTEM) which assesses haemostasis 
from the start of clot formation to fibrinolysis gives earliest results within ten minutes.  
 
 
 AIMS AND OBJECTIVES 
To compare the diagnostic ability of Rotational Thromboelastometry (ROTEM) with the 
standard coagulation profile to detect coagulation defects in acquired bleeding disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Methods 
A total of 138 subjects - 70 patients who presented with acquired bleeding disordersand 68 
subjects diagnosed to be normal on the basis of a complete coagulation work up were included as 
the cases and controlsrespectively. All samples were subjected to standard coagulation profile by 
automated methods and ROTEM analysis which included Clotting Time, Clot Formation Time, 
Alpha Angle, Maximum Clot Firmness and Maximum Lysis. 
 
Results 
The Maximum Clot Firmness shows a very good correlation with serum fibrinogen levels (k 
value - 0.807; p<0.000; Sensitivity - 88%; Specificity - 92%), and good correlation with platelet 
count (k value - 0.793; p< 0.000; Sensitivity - 86%, Specificity-92%), whereas Clot Formation 
Time showed moderate correlation with activated partial thromboplastin time, platelet count and 
fibrinogen levels.Alpha angle had a moderate correlation with platelet count and 
fibrinogen.Clotting time had a poor correlation with prothrombin time and activated partial 
thromboplastin time. 
Discussion and Conclusion 
The achievement of haemostasis   is a crucial factor for determining patient outcomes in acquired 
bleeding disorders. The gold standard test to diagnose coagulopathy is the standard coagulation 
profile. Rotational thromboelastometry correlates well with standard coagulation parameters. 
This test which is performed on whole blood showed interpretable results within 10 minutes, 
whereas standard coagulation profile required an average of 45minutes. In view of the good 
correlation to the standard coagulation profile, it appears that Rotational 
Thromboelastometryresults can be safely used to implement early transfusion therapy for 
haemorrhage. 
Keywords: coagulopathy, rotational thromboelastometry, maximum clot firmness, alpha angle, 
clot formation time, 
INTRODUCTION  
Bleeding disorders comprise a varied group of diseases due to the malfunction of blood vessels, 
coagulation proteins and platelets. The clinical spectrum varies from a mild bleeding diathesis to 
severe hemorrhage which can lead to death. It can be due to either quantitative or qualitative 
abnormalities of coagulation proteins or platelets. Mild bleeding symptoms like easy bruising, 
epistaxis, are more common than severe life threatening hemorrhage. The symptoms may 
sometimes reveal an underlying malignant bone marrow pathology.  
Bleeding-history assessment tools can be used to assess the patient. A high bleeding score 
indicates a significant bleeding disorder but there can be an overlap of scores for individuals with 
mild bleeding disorder and without any bleeding symptoms.(1) The bleeding histories are 
subjective and therefore significant symptoms may  sometimes be ignored and considered as 
normal while negligible or minor symptoms be given undue consideration.  
The bleeding disorders are broadly classified into inherited bleeding disorders and acquired 
bleeding disorders. Inherited bleeding disorders are diseases due to hereditary abnormalities of 
proteins or platelets which are necessary for blood clotting. The most common causes include 
Hemophilia A which is due to deficiency of coagulation factor VIII, von Willebrand disease 
which is caused by a defect or deficiency of von Willebrand factor and Hemophilia B or the 
Christmas disease, due to the deficiency of factor IX. Among the platelet disorders include 
Bernard Soulier Syndrome and Glanzmann Thrombasthenia. 
 
 
Acquired bleeding disorders occur due to depletion, reduced synthesis, or inhibition of platelets 
and coagulation factors. The causes include disseminated intravascular coagulation, Vitamin K 
deficiency or antagonists, acquired inhibitors to coagulation factors, liver transplantation, renal 
causes, use of anticoagulant and traumatic bleeding. Disseminated intravascular coagulation can 
occur in various clinical conditions like septicemia, acute promyelocytic leukemia, abruption 
placenta, trauma. The most common condition resulting from a coagulation factor inhibitor is 
acquired Hemophilia A. The acquired platelet function disorders include drug usage,(Aspirin, 
Clopidogrel, Prasugrel) food additives, myeloproliferative neoplasm and Paroxysmal Nocturnal  
Hemoglobinuria. 
 
Overview of hemostasis  
The hemorrhage can be due to interference with the platelet plug formation, interference with 
blood coagulation proteins, or interference with both. The coagulation occurs by two pathways 
which includes the primary extrinsic pathway and the contactor intrinsic pathway (accessory 
pathway). Injury to the vessel wall results in exposure of tissue factor to factor VIIa which then 
forms the extrinsic tenase complex. The factors IX and X converts to factors IXa and Xa 
ultimately forming the intrinsic tenase complex and prothrombinase complex.The collective 
function of  intrinsic, extrinsic tenase and the prothrombinase complexes results in thrombin 
generation. The thrombin acts as a procoagulant and anticoagulant. The thrombin splits 
fibrinogen into fibrinopeptides. The thrombin also activates factor XIII to form a cross-linked 
fibrin clot. (Figure 1) 
 Figure 1- The coagulation pathway 
Acquired bleeding disorders (ABD) are commonly occurs due to depletion, reduced synthesis, 
inhibition of coagulation factors and platelets. The clinical picture ranges from mild bruises to 
life-threatening hemorrhage. The location, frequency, severity of bleeding  depends on the  cause 
of bleeding disorder .A complete medical, surgical, family, social, and medication history is 
necessary in understanding the etiology. The basic laboratory test prothrombin time, activated 
partial thromboplastin time, serum fibrinogen, platelet count, help in exposing the cause of 
bleeding. Management depends on the history and laboratory tests. The treatment decision 
includes administration of vitamin K, blood, plasma, cryoprecipitate or platelets transfusion and 
blood derivatives like factor concentrates.  
Acquired bleeding disorders are the most frequent causes of hemorrhage encountered in the 
practice of hematology. The various type of disorders include drug induced hemorrhage, 
acquired factor deficiencies, disseminated intravascular coagulation, acquired coagulation factor 
abnormalities like acquired Hemophila A, acquired von Willebrands disease, immune 
thrombocytopenia, non–drug induced, acquired platelet function disorders, vitamin K deficiency, 
liver and renal disease, hypothyroidism, surgical bleeding, scurvy, hypothyroidism and Cushings 
syndrome. The most common cause is a drug-induced defect. (2)  
An acute bleed should be managed immediately with blood products, factor concentrates 
antifibrinolytics before the results of coagulation   test    are available. The investigations for a 
bleeding problem includes prothrombin time, activated partial thromboplastin time, platelet 
count and fibrinogen level.  Abnormalities, if detected, require further evaluation to determine if 
the cause is a fibrinogen disorder, platelet disorder or coagulation factors deficiencies.  
Rotation thromboelastometry (ROTEM) are point-of-care devices that assess hemostasis from 
the start of clot formation to fibrinolysis. This   system has four separate measurement channels 
which allow the independent tests like EXTEM, INTEM, APTEM AND HEPTEM and a 
computer for automatic analysis. This study was done to assess the efficiency of rotational 
thromboelastometry in comparison to the standard coagulation profile in assessing coagulopathy 
in acquired bleeding disorders. 
REVIEW  OF LITERATURE 
History  
In 1628, William Harvey described the circulatory system.(3) In 1825, the first successful 
human-to-human blood transfusion was reported by James Blundell, an obstetrician and 
physiologist at Guy’s Hospital in London who transfused women with postpartum 
haemorrhage.(4) During World War I and II blood transfusion was given to bleeding soldiers to 
combat the war injuries.(5)  
Ratnoff and Davies proposed the coagulation pathway, which was composed of a series of 
proteolytic reactions starting with factor XII and terminating in the formation of clot. (6) The 
prothrombin time was introduced by Dr Armand Quick in 1935 which was used to assess 
coagulopathy in Hemophilia and was later used in acquired bleeding disorders.(7)  In 1936, 
Warner et al developed a two-stage prothrombin assay, based on the fact   that plasma, serum 
factors and tissue factor are required for the conversion of prothrombin to thrombin. (8) The 
partial thromboplastin time was illustrated by Langdell and was used to assess Hemophila. The 
platelet count estimation was done with the help of automated platforms since the early 60’s.(9)  
Homeostasis  
In the beginning of twentieth century, Paul Morawitz, a German physiologist put forward the 
classic theory of coagulation. He hypothesized that thromboplastin converts prothrombin to 
thrombin converting fibrinogen to the fibrin.  These clotting factors were named as fibrinogen, 
prothrombin, thromboplastin, tissue factor membrane and calcium. The factors that were 
discovered later   were assigned consecutive Roman numerals. The activated forms  were 
depicted by  lower case a .(6) 
The  hemostatic  system or the coagulation cascade was  based on the waterfall hypothesis of 
Ratnoff and Davies(9) and MacFarland,(10) who independently reported a series of proteolytic 
reactions beginning  with factor  XII  activation and ceasing with the thrombin converting 
fibrinogen to form a thrombus. The shortcoming of this  hypothesis  was that factor XII 
deficiency was not associated with bleeding.(11) The cofactors for factor XII activation; 
prekallikrein  and  high- molecular-weight  kininogen deficiencies  also were not associated with 
hemorrhage.(12) 
Over the  decades these pathways  have  been modified  The   newer  concept  of  coagulation  
represents  a complex process of procoagulant and fibrinolytic actions which  occur 
simultaneously. 
The Vitamin K–dependent protein family 
Vitamin K–dependent factors are produced in the liver. These factors act as either procoagulant 
or anticoagulant. These include factors  II,VII, IX, X and the anticoagulants factors  protein C, 
protein S, and protein Z. (13) Vitamin K is essential for the synthesis of these clotting factors  
which undergoes γ-carboxylation.(14) This alteration adds a  negative  charge  to  the  molecules  
that  enables proteins  to  interact  with  Calcium  and  surface of membrane. Vitamin K–
dependent protein complexes are composed of a serine protease enzyme, a cofactor, and a 
negatively charged membrane surface. The four vitamin K–dependent complexes include the 
extrinsic tenase complex ( FVIIa and tissue factor), the intrinsic tenase complex (FIXa–FVIIIa), 
the prothrombinase complex (FXa–FVa), and the anticoagulant protein Case complex 
(thrombin–thrombomodulin).   
Cofactor   proteins 
1. Cell bound cofactors - Tissue factor and thrombomodulin. 
2. Soluble  plasma-derived procofactors -  factor V, factor VIII  and von Willebrand factor 
.(6) 
Tissue factor  
A cofactor for factorVIIa in the extrinsic tenase  complex. The   release of tissue factor to the 
circulation initiates the procoagulant pathway. (15)  
Thrombomodulin  
A protein expressed on the surface of vascular endothelial cells. It acts as a cofactor for the 
activation of protein C. (16) The formation  of  protein C by the thrombin–thrombomodulin 
complex causes  inactivation of factor Va and factor  VIIIa.(17)   This complex has an 
antifibrinolytic action by activating  the fibrinolysis inhibitor, thrombin activatable fibrinolysis 
inhibitor (18) 
Factor VIII  
The  factor VIII also known as the  Antihemophilic factor circulates in plasma in complex with 
von Willebrand factor(19) The von Willebrand Factor–free factor VIIIa forms a complex with  
factor  IXa,  Calcium  and  platelet membrane    resulting  in  the formation of  intrinsic  tenase  
complex.     
 
The Intrinsic Accessory Pathway Proteins  
The proteins of the intrinsic or accessory   pathway includes factor XII, prekallikrein, and high 
molecular-weight kininogen. (20) The function of the accessory pathway is not fully  
understood.(21) This pathway play an important role in disseminated intravascular coagulation 
(DIC) associated with the systemic inflammatory response syndrome and also   in  
cardiopulmonary  bypass  where there is contact  between blood and synthetic surfaces.(22) The 
factor XI is an intersection point for the two pathways. Individuals with factor XI deficiency 
have a inconsistent bleeding phenotype proving that   there is a  role for factor XI in hemostasis. 
(23) The  propagation phase of thrombin generation is carried out by FXI a.(24)  
The clot formation inhibitors in the blood include antithrombin, heparin cofactor II, tissue factor 
pathway inhibitor and protein C inhibitor.   
The   integrity of vasculature is necessary for   normal   hemostasis. The  endothelium that lines 
the interior of blood vessels, plays an important role  by providing a structural barrier to blood 
regulates blood pressure and  deposits  an  intricate  basement  membrane  and extracellular  
matrix. Massive bleeding can occur due to abnormalities  of  the  endothelial  cells.(25)  Studies 
by Ware and Seegers had identified that phospholipid is  required for coagulation.(26) The 
damaged vascular tissue activated platelets produce phospholipids. The endothelial damage 
release von Willebrand factor that causes platelet aggregation and adhesion to the sub 
endothelium leading to thrombus formation. 
Platelets are small, cell fragments, derived from megakaryocytes contribute to procoagulant 
events and fibrinolytic process. The platelets contain secretory granules: α-granules, lysosomes, 
and dense granules. The activated platelets adhere to each other, endothelial cells, leukocytes, 
and  components  of  the  subendothelial  matrix.(6)The  phosphatidyl serine  surface  platelets 
are  present a procoagulant surface to the circulation. The  activated platelets express factor Va 
binding sites (27) Factor Xa bind to effector cell protease receptor-1 molecules which are present 
on activated platelets.(28) 
The presence of receptors on the  platelet surface thrombin, adenosine diphosphate, and 
thromboxane A2 to channel other platelets into the hemostatic. The close contact between 
platelets promote stabilization of the hemostatic plug (29) 
Clot proteins  
Fibrinogen helps in hemostasis to prevent hemorrhage. It supports inter platelet aggregation. 
Fibrinogen controls thrombin activity to form a fibrin clot.   Fibrinogen consists of polypeptide 
chains with the NH2 termini cross linked to each other. Fibrinogen   increases  during 
inflammation as it is an acute phase reactant.(30)  
Fibrinolysis or the removal of blood clots includes primary fibrinolysis and secondary 
fibrinolysis. The primary fibrinolysis is a normal process while secondary fibrinolysis is the due 
to a medicine or a medical disorder. Plasminogen  is  the  precursor  of  the  plasmin,  which is  
the  primary  catalyst  of  fibrin  degradation.(31)  The activation of plasminogen occur through 
three pathways: (a) the intrinsic activator system (b) the extrinsic activators (c)an activator 
system involving fibrinolytic drugs. The plasmin degrades fibrin producing degradation 
products.  
Initiation  
The injury to the vessels results in a triggered response resulting in platelet and fibrin deposition.  
The  coagulation enzymes anchors, assembles, and express on the activated platelet   
membrane.(32)  As vascular damage progress, more activated platelets gets anchored which 
allows the assembly of more coagulation enzymes leading to increased fibrin formation. When 
the  vascular system is perturbed the extrinsic tenase complex which is the tissue factor–factor 
VIIa and the calcium complex , comes into play.(33)  The extrinsic tenase complex  activates 
low levels factor X and factor IX to Xa  and factor IXa.(34) The time interval in which factor Xa 
generates thrombin is called as  the initiation phase of blood coagulation.(35)  During the 
initiation phase, circulating blood cells and procoagulant proteins are activated, and  a initial  
fibrin network is formed.(36)  
Amplification 
Thrombin also activates factor XI to Xia  , initiating the accessory pathway that promotes  factor 
IX activation.(37)  The aggregated platelets and fibrin due to the thrombin formation are the 
major constituents of the initial vascular plug formation. The cofactor factor VIIIa  combines on 
activated platelets with the factor IXa to form the intrinsic tenase complex  which  activates  
factor X. (38) Factor  Xa  formed from factor X  combines  with  factor  Va  on  the platelet 
membrane to form the prothrombinase  complex which generates thrombin. (24) The 
prothrombinase and the intrinsic tenase complex are protected from inhibition by antithrombin. 
 
Propagation  
The  aggregate  of  activated  platelets will cause an  increase in  intrinsic tenase and 
prothrombinase complex formation  on  their  surfaces  with the help of specific  platelet  
receptors.  These platelet-bound complexes cause   the propagation stage of the reaction resulting 
in the production of enormous quantities   of thrombin. (39) This stage is independent of tissue 
factor and is continuous. Prothrombinase complex formation requires generation of factor Xa.  It 
is formed through the intrinsic tenase and the extrinsic tenase complexes.  The   concentration  of 
factor  Xa  is  the  rate-limiting  factor for   formation of prothrombinase complex.(40)  
 The coagulation mechanism is susceptible to factor V  and platelets  and is affected in case of 
congenital deficiencies, thrombocytopenia, abnormal platelet function or pharmacologic 
interventions.(41) Nearly 95% of thrombin  is produced  during the propagation phase after 
formation of fibrin clot.(42)  
Termination  
When blood flow stops due to  the formation of a fibrin clot, the TFPI,  antithrombin,  heparin  
cofactor  II, α2-macroglobulin, α1-antitrypsin, and protein C inhibitor, inhibit  the  various  
reactants  as  they  dissociate  from  their respective complexes.(43) In the intact blood vessel 
surrounding the newly formed clot, procoagulant enzymes are rapidly reduced under normal 
circumstances. The thrombin, factor IXa, and factor Xa are repressed by the excess antithrombin 
molecules.  The thrombin bind with thrombomodulin  and is  converted to  an  anticoagulant  
enzyme from a  procoagulant state.(44)  This complex activates protein C, which causes decrease 
of intrinsic factor tenase and prothrombinase. . These intravascular mechanisms function against 
occlusion of the blood vessel. 
Elimination  and Fibrinolysis 
The hemostatic clot is composed of aggregated platelets and    fibrin.  There are some plasma 
proteins and blood cells which are trapped within the clot. Finally clot disintegration occurs with 
the help of plasmin which maintains hemostatic balance. The tissue plasminogen activator 
generates plasmin at the fibrin surface and governs fibrin  homeostasis,  and  u-PA  generates 
pericellular plasmin.(45)  The t-PA and plasminogen bind to the fibrin surface which results in 
augmented plasminogen activation. Fibrinolysis  is  regulated  primarily  by  PAI-1 (46)   PAI-2, 
α2-antiplasmin,  and TAFI. Antiplasmin is the primary inhibitor of plasmin. The α2-antiplasmin, 
bound covalently by factor XIIIa blocks plasmin binding and decrease plasminogen 
activation.(47) The elimination phase begins with tissue repair by dissolving the fibrin–platelet 
clot generated earlier in hemostasis. The plasmin clears the fibrin clot and also removes damaged 
tissue. If a sufficient hemostatic plug is not formed to arrest blood flow, it can result in 
pathologic  hemorrhage.   
 
Figure 2: Regulation of coagulation cascade  
Acquired  bleeding disorders 
Acquired bleeding disorders are commonly seen in the practice of hematology. The symptoms 
vary from mild bruises to life threatening hemorrhage. The clinical, family, social, and 
medication history site, frequency and the age of onset aids in the diagnosis of the type of 
disorder. These disorders can be due to consumption, reduced synthesis, inhibitors to either 
coagulation factors or platelets. The treatment depends on the cause of bleeding and includes 
blood component transfusion, factor concentrates administration of vitamin K and anti 
fibrinolytic agents. 
Disseminated Intravascular Coagulation 
Disseminated intravascular coagulation (DIC) is one of the most common acquired bleeding 
disorder. Disseminated intravascular coagulation is the widespread activation of coagulation 
system,that results in the intravascular formation of fibrin leading to thrombotic occlusion of 
small blood vessels. Intravascular coagulation cause decreased blood supply to organs and, in 
combination with hemodynamic and metabolic derangements cause organ failure. Ongoing 
coagulation causes depletion of platelets and coagulation proteins which results in severe 
bleeding. Hemorrhage will be the presenting symptom in such cases and this  can complicate 
decisions about treatment.(48) This event causes utilization of coagulation factors which can lead 
to bleeding disorder if the consumption is high. This condition is mainly associated with 
septicemia, malignancy, and fulminant liver disease. DIC can  also occur in severe trauma, toxic 
poisonings, snake bite, placental abruption and amniotic fluid embolism.(49) The most important 
clinical conditions associated with DIC are listed in Table 1. The clinical feature are usually 
unpredictable. There can be a disseminated bleeding, like an ooze from multiple sites. Major 
bleeding manifestations and intracranial bleeds are relatively rare. The occlusion in the  
vasculature of organs by microthrombi results in necrosis causing  multiple organ failure.(50) 
 
 
CLINICAL CONDITIONS  THAT CAUSES  DIC 
Sepsis 
Trauma , Burns or heat stroke 
Malignancy – Solid tumours, AML M3 
Obstetric conditions – Amniotic fluid embolism, Placental abruption, HELLP 
Vascular abnormalities- Aortic aneurysms, Kasabach-Merritt syndrome 
Allergic reactions 
Immunological reactions 
Table 1 - Causes of Disseminated Intravascular Coagulation 
Pathogenesis   
The endothelial cells and activated mononuclear cells generate pro inflammatory cytokines that 
cause release of tissue factor which starts coagulation. The suppression of anticoagulant action   
and     inhibition of fibrinolysis causes intravascular fibrin deposition.   
Clinical  manifestations 
Disseminated Intravascular Coagulation in Infectious Disease 
Infections are the most common causes of DIC. Septicemia is the most common clinical 
condition associated with disseminated intravascular coagulation. Mostly all microorganisms can 
cause disseminated intravascular coagulation and bacterial infection is most frequently related to 
the development of this syndrome. The triggers of the activation of coagulation in septicemia 
patients are cell membrane components of the microorganism which includes  
lipopolysaccharide , bacterial exotoxins which induce a generalized inflammatory response 
causing release of cytokines.(51) 
Newborns  and post splenectomy patients   are prone to  DIC.(52) Hemorrhage can be further 
aggravated by thrombocytopenia. Bacterial infections are more commonly   associated with the 
syndrome.  Viruses , protozoa , and fungi can cause DIC.(53) In septic patients can present with 
thromboembolic  disease or multiple organ dysfunction.(48)Patients may present with severe 
bleeding in some cases.(54) Purpura  fulminans is  lethal form of DIC  which affects  infants  and  
children  in which the skin over the extremities undergo hemorrhagic necrosis due to diffuse 
thrombi in small blood vessels . This disorder occur due to  meningococcemia,streptococcal 
disease  or staphylococcus.(55)  
Disseminated  Intravascular Coagulation in Trauma and Burns. 
Traumatic hemorrhage resulting in trauma induced coagulopathy is associated with mortality   in 
severely injured patients.  The blood  loss following severe injury can lead to disturbance of the 
blood coagulation system causing  trauma induced coagulopathy (TIC) which is due to hypo 
perfusion of tissue and loss and severe tissue injury.(56) The severity of Disseminated 
Intravascular Coagulation depends on time gap between trauma and management. Provision of 
prompt medical care can reduce the risk of DIC. The massive release of Tissue factor to the 
blood circulation, hemorrhagic shock, cytokines are possibly the factors that initiate DIC .TIC is 
due to dysfunction of inflammation, anticoagulation, and cellular systems. The underlying 
mechanisms of TIC have not been fully revealed. In addition dilutional coagulopathy, 
hypothermia, and acidosis also contributes to TIC. (56) Surgical excision of burn wounds causes  
severe bleeding leading to  coagulopathy .(57) 
Disseminated Intravascular Coagulation in Obstetric and Gynecological 
Complications 
 
Postpartum hemorrhage (PPH) is significant problem in obstetrics and a leading cause of 
maternal deaths worldwide. The  incidence of PPH is approximately 5%-20% of labors (58) with 
the highest rates in developing countries. Postpartum hemorrhage is associated with disseminated 
coagulopathy. The activation of coagulation system  results in   reduction of platelets and 
coagulation factors,  aggravating bleeding  due to consumption.(59) 
The majority of cases due to  obstetric pathology. The major obstetrical cause of postpartum 
hemorrhage is uterine atony which can lead to coagulation failure. (60) Placental abruption   
causes perinatal death and can lead to DIC. (16) Antenatal women with hypertension at highest 
risk. DIC can occur in such situations due to of enormous amounts of tissue factor in the blood 
circulation. The leakage of thromboplastin-like product from placenta which occurs in abruption 
leads to disseminated intravascular coagulation.(61) 
 In amniotic  fluid  embolism , the  fluid enters   the  maternal  circulation  through  tears  in  the  
chorio-amniotic membranes and uterine  rupture. DIC is caused by the tissue factor present in 
amniotic fluid. The autopsy finding in patients who died of amniotic fluid embolism had 
revealed   fetal debris and the   meconium, in the amniotic fluid causes thrombus formation and 
fibrinolysis, leading to the occlusion of the pulmonary arteries causing breathlessness, cyanosis, 
shock, acute corpulmonale, left ventricular dysfunction and convulsions. These symptoms are 
followed by severe bleeding in some patients. (62) 
    
Disseminated Intravascular Coagulation in Malignancy  
Patients with solid tumors are susceptible to DIC that can exacerbate hemorrhage. The risk 
factors  include old age, stage of the disease, chemotherapy , infection,  liver metastases .(63) In 
acute promyelocytic leukemia, increased fibrinolysis causes hemorrhage. Studies in mice model 
suggested that  annexin II have a role in acute promyelocytic leukemia  coagulopathy.(64)  The 
blasts overexpress annexin II, a receptor for tissue plasminogen activator (tPA), and 
plasminogen, and increases plasmin generation. The brain and lungs are the most common sites 
affected which can lead to fatal hemorrhage.(65) 
Solid  tumor  cells express procoagulant molecules like tissue factor , which  forms a complex 
with factor VII and  activate factors IX and X,  an endopeptidase  which activates factor X.(66) . 
Nearly 15% to 20% of acute lymphoblastic leukemia, present with disseminated intravascular 
coagulation.(63) 
Disseminated Intravascular Coagulation With Vascular Disorders  
Disseminated intravascular coagulation can be caused by vascular anomalies.  Aortic  aneurysms 
can cause   localized  platelet and fibrinogen  consumption   and  can produce  coagulation  
abnormalities  and  bleeding.(67) Kasabach  and Merritt described bleeding in patients with  
giant  cavernous  hemangiomas,  that cause  consummation of  platelets and fibrinogen.(68) 
Disseminated Intravascular Coagulation With Toxic Reactions or Snake Bites  
The venom of vipers and rattlesnakes, can produce a coagulopathy similar to that of DIC.(69) 
The venoms of these snakes contain enzymes that function by the following mechanism:     
a)  release fibrinopeptide A  
b) activate prothrombin even in the absence of calcium 
c)  activate  factors  X  and  V   
d)  degrade  fibrinogen  
e) cause platelet  aggregation  
f)   inhibit  platelet  aggregation   
g) Damage endothelial cells and cause bleeding, tissue ischemia, and edema. 
The  victims of snake bites rarely have excessive hemorrhage.(6) 
 
Liver disease and orthotopic   liver transplantation 
Low platelet counts is frequent in liver disease and the  platelet counts range from 30 - 100× 
10
9
/L.(70) Platelet aggregation also occurs which causes prolonged bleeding time. (71) The 
increase of tissue plasminogen activator in plasma and decrease of the naturally-occurring 
inhibitors of plasmin results in hyperfibrinolysis  (72) 
Even in a scenario of deranged hemostasis , routine hemostasis tests fail to reveal the bleeding 
tendency in cirrhosis (73–75). The  low procoagulant factors are balanced by decrease of 
naturally occurring anticoagulants.(76) Plasma hyperfibrinolysis has been reported in patients 
with chronic liver disease (36)  
In liver transplantation age, severity of liver disease, hemoglobin and plasma fibrinogen values 
determine the bleeding crisis. During the hepatectomy and the anhepatic phase, hemorrhage 
occurs due to decrease in clotting factors either due to surgical bleeding or the primary disease. 
The  coagulopathy exacerbates on infusion of crystalloid, colloid, or blood products.(77) At the 
time of graft reperfusion, further depletion  of all coagulation factors, antithrombotic factors  
occurs which further aggravate bleeding. (37)  
 
 
Renal disease  
Bleeding diathesis have been reported in patients with uremia especially when they undergo 
surgery and other invasive procedures. Life -threatening conditions like  pericardial tamponade, 
intracranial bleeding, and gastrointestinal bleeding are also seen in these conditions.(78) The 
patients have a  platelet dysfunction and an abnormal platelet–vessel wall interaction.(79)  
Various studies have shown that contact of fibrinogen to ADP-stimulated platelets is impeded 
and the interaction between vWF and the GPIIb-IIIa is disturbed.(80)  
Vitamin K deficiency 
Vitamin K deficiency is usually seen in newborns especially those with mal absorption or on 
broad-spectrum antibiotics treatment. Adults who have  reduced stores of vitamin K or due to 
warfarin overdose, rodenticide poisoning (called super warfarins as they have the same 
mechanism of action like warfarin)  are prone for  bleeding diathesis.(81,82) 
 
Vitamin C deficiency (Scurvy) 
 This is a rare condition especially in developed countries, when patient presents with 
perifollicular hemorrhages and gum bleeding (83). There are case reports of scurvy patients 
presenting with hemarthrosis.(84) 
Massive  transfusion 
Massive transfusion is defined as  1) transfusion of  more than 10 red  cell concentrate  units, 
which is nearly the total blood volume of an average adult patient, within 24 h  2) transfusion of  
more than four  red cell concentrates  in 1 h with  expectation of continued need for blood 
product support 3) replacement of fifty percent of the total blood volume by blood products 
within 3 h.(85–87) The hemostatic defects in  such patients have multifactorial pathogenesis 
causing early trauma induced coagulopathy  leading to further transfusion support.(88) 
Coagulopathy  can be aggravated by the  infusion of crystalloids and  blood products The 
transfusion of red cell  units without additional clotting factors or platelets  causes further 
impairment of hemostasis  due to dilutional coagulopathy , thrombocytopenia ,acidosis , 
hypocalcaemia and  hypothermia from refrigeration.(89,90) 
 
Acquired   coagulation factor inhibitors 
These disorders can be due to immune or nonimmune causes. Antibodies are produced against 
the coagulation factors which causes hemorrhagic manifestations. Acquired Hemophila A  is a 
rare bleeding disorder, autoimmune in  origin  with an incidence of 0.2 to 1.0 cases/million 
population per year.(91) The hemorrhages in patients with acquired hemophilia usually affect 
soft tissues. (92)The factor VIII autoantibodies  rarely in  pregnancy causing bleeding symptoms. 
(93) Acquired Hemophila B cases are very rare. A few cases has been reported so far. (94)  
Acquired factor V inhibitor is another rare entity in the elderly,  that presents with hemorrhagic 
manifestations. The probable causes for the inhibitor development include exposure to bovine 
thrombin, antibiotics, surgery and malignancy. (95)  Acquired FX deficiency  presents with 
variable symptoms, and there are various case studies showing association with 
amyloidosis.(96,97) 
Hypothyroidism  
There are case reports on association of hypothyroidism with acquired von Willebrand disease 
presenting with bleeding manifestations .The coagulation defects were corrected with the 
management of hypothyroidism.(98,99)  
Cushing syndrome  
Easy bruisability and menstrual disturbances are features of Cushing syndrome or treatment with 
systemic or topical glucocorticoids.(100) 
 
Drug -induced platelet dysfunction  
Aspirin, NSAIDs, other platelet function inhibitors are common causes of drug induced 
bleeding.(101,102) 
 
Anticoagulation  
Acute bleeding following anticoagulant therapy might be severe or even life-threatening and the 
frequency ranges from 2% to 13%. Drugs like Warfarin inhibits the action of vitamin K.(Figure 
3) The management is the reversal of anti-coagulation depends on the situation, as per the 
international normalized ratios (INR), severity of bleeding and indication. The management 
includes reversal of anticoagulant, vitamin K injection. In emergency situations   fresh frozen 
plasma and coagulation factor concentrates can be used. (69)  
 
Figure 3 – Mechanism of action of Vitamin K antagonists. 
 
LABORATORY ASSESSMENT 
STANDARD COAGULATION PROFILE 
The diagnosis of disseminated intravascular coagulation is based on clinical presentation and an 
altered standard coagulation profile.  A rapidly decreasing platelet count is an important feature 
of DIC.(12) Due to consumption of coagulation factors , both PT and aPTT are prolonged. The 
APTT can be very shortened  in early acute DIC due to the presence of activated coagulation 
factors.(103)  Fibrinogen depletion occurs in severe DIC but can be high or normal since it is an 
acute phase reactant.(104) In severe cases of DIC, microangiopathic hemolytic anemia may be 
seen .Disseminated intravascular coagulation can be diagnosed on the basis of the following:                                        
 a) An underlying cause like sepsis, trauma, burns. 
b) Platelet count of less than 100,000 per cubic millimeter/ rapid decline in the platelet count. 
c) Prolonged   prothrombin time and the activated partial-thromboplastin time  
d )The   presence  of  fibrin-degradation product. 
e) Depleted plasma fibrinogen. (48)  
Low plasma fibrinogen levels of less than 50 mg/dL are associated with severe hemorrhage   in 
DIC. Fragmented red blood cells or schistocytes will be seen in DIC cases. Toxic changes in 
leukocytes will be present in the smear of sepsis patients.(105) 
 
 
 
                                                          
 
 
Figure 4- Peripheral smear showing schistocytes in DIC 
 
 
LIMITATIONS OF STANDARD COAGULATION PROFILE 
The PT and aPTT tests identify only partially if any coagulation defects are present. These tests 
also give a high number of false positive and false negative results.(106)In obstetrics pre-
procedural coagulation screening is usually not recommended. A complete bleeding and 
medication history is considered more effective than doing coagulation profile. If there is  a 
hemostatic impairement like placental abruption , coagulation profile is done.(107)    
 
THROMBIN GENERATION TIME 
Thrombin which acts as a procoagulant and anticoagulant is an important enzyme of the 
coagulation cascade. The   thrombin generation is one of the prime steps in coagulation. The 
thrombin generation test is suitable for its assessment. This test detects both pro- and 
anticoagulant processes, so it can be applied for the detection of thrombosis and bleeding.  
Anticoagulant therapy can be monitored by this test.  This assay  can be used to assess  bleeding 
severity , monitoring treatment and inhibitor by passing therapy in Hemophilia cases.(108) 
THROMBOELASTOGRAPHY 
Thrombelastography is a test which measures viscoelastic properties of blood clot. This test is 
used in trauma settings for managing acute coagulopathy and helps in taking decision regarding 
transfusion. This test can be used as a point of care test and can be performed by trained 
personnel. Moreover the technique requires standardization. Partial results which can be used for 
bleeding assessment is available in  a short time, while  whole test  may require long time 
periods as other conventional tests. The clot strength and fibrinolysis can be assessed by 
thromboelastography. (Figure 4) Clot strength measure can determine whether there is 
coagulopathy Thrombelastography can diagnose fibrinolysis and can be used to decide on anti-
fibrinolytic drugs, cryoprecipitate and fibrinogen concentrate therapy. (109) 
 
 
 
Figure 5- Normal thromboelastography 
 
ROTATIONAL THROMBOELASTOMETRY 
Background 
Rotational thromboelastometry is a point of care (POC) viscoelastic tests of hemostasis which 
detects clot formation and dissolution.  ROTEM is a variation of the TEG technology originally 
described by Hartert in1948. This test provide a visual evaluation of clot formation, propagation, 
stabilization and  lysis under low shear conditions that is  similar to  those present in the vena 
cava , large veins, and the arterial system.(110)This process is analyzed by a software. 
 
 
  
Figure 6- Thromboelastometry ( ROTEM)   machine 
Technology 
Rotational thromboelastometry evaluates the clot formation kinetics and strength by measuring 
the amount of a rotational force that is transmitted to an electromechanical transduction system 
by developing clot. . In this system, a cylindrical cup which is fixed and containing a 340 µl 
 
whole blood sample and a pin suspended on a ball bearing mechanism initially oscillates 
through 4° 75′ every 6 sec through application of a constant force. As the strength of the clot 
increases the rotation of the pin is hindered it is detected optically using a image sensor system. 
ROTEM device is capable of analyzing 4 samples simultaneously. ROTEM provides automated 
pipetting. (111) 
 
Parameters   (Figure 6) 
Clotting Time (CT) 
It is the time from the beginning of the test by adding the clot activator until the time when 
amplitude of 2 mm is achieved.  
Clot Formation Time (CFT) 
 It is the time between 2 mm amplitude and 20 mm amplitude of the clotting signal. 
Alpha Angle (α)  
 It is defined as the angle between the middle axis and the tangent to the clotting curve through 
the 2 mm amplitude point. It describes the kinetics of clotting. 
Maximum Clot Firmness (MCF) 
 It is the measure for the firmness of the clot and therefore the clot quality. It is the maximum 
amplitude that is reached before the clot is dissolved by fibrinolysis and the clot firmness falls 
again. 
Maximum Lysis (ML) 
 It is the degree of fibrinolysis relative to maximum clot firmness achieved during the 
measurement. 
 ROTEM Assays 
 
INTEM 
 
Contact activation.  
Reagent - phospholipid and ellagic acid as activators  
Provides  information similar to that of the APTT. 
EXTEM Tissue factor activation.  
Reagent contains tissue factor as an activator. 
Provides  information similar to that of the PT. 
APTEM Aprotinin  for inhibiting fibrinolysis 
 Used  in conjunction with EXTEM FOR assessing  fibrinolysis. 
HEPTEM Contains lyophilized heparinase for neutralizing unfractionated heparin 
 Used in conjunction with INTEM to assess heparin effect. 
FIBTEM Utilizes cytochalasin D, an actin polymerization inhibitor to block the platelet 
contribution to clot formation.  
Used in conjunction with EXTEM reagent for qualitative analysis of the 
fibrinogen contribution to clot strength independent of platelets. 
NATEM  
 
Native whole blood sample analyzed following only recalcification. 
Impractical for clinical use given long CFT time 
 
  
The use of rotational thromboelastometry in transfusion support assessment allows targeted 
hemostatic approach. This strategy reduces blood usage as compared to a blinded approach to 
transfusion on the basis of laboratory tests with long turnaround times. The usual turnaround 
time for PT, aPTT, fibrinogen concentration and platelet count is generally long (nearly 45- 60 
min) to determine the therapy in severely bleeding patients.  The initial variables of ROTEM are 
available within 15–20 min.(112)  
 
APPLICATION IN CLINICAL CONDITIONS 
CARDIAC SURGERY  
Hemorrhage following cardiac surgery is a common clinical crisis. There are various studies on 
the use of ROTEM for analysis of hemorrhage which appear to reduce the transfusion 
requirements as compared to standard coagulation profile. Studies have shown that rotational 
thromboelastometry can predict thrombocytopenia and hypofibrinogenemia in cardiac surgery 
using the clot amplitude after 5 minutes and the turnaround time of ROTEM was less than the 
conventional laboratory tests. (112) Studies in cardio thoracic  patients  have shown that  
ROTEM helps in  detection of causes for postsurgical hemorrhage (113)  Another study showed 
that  thromboelastometry can be used in the study of the coagulation profile of cardiac surgery  
patients in post perfusion period. This gives  information regarding hemostasis disorders and aids 
in the management.(114) 
Thromboelastometry was also used to ascertain the effect of ex vivo addition with fibrinogen or 
platelet concentrate that caused shortened clotting time and improved clot strength in a dose-
dependent manner. This combination of fibrinogen and platelets improved the clotting time and 
strength. The addition of platelets promoted platelet aggregation in a dose-dependent manner 
while fibrinogen had no effect. The combination of fibrinogen and platelets improved platelet 
aggregation less than when the platelets were used alone. In cardiac surgery patients, the use of 
platelet and fibrinogen concentrates on blood samples had an additive effect on clot formation as 
compared to the individual components. These results  had an impact on clinical transfusion 
protocols.(115)  
 
TRAUMA 
Trauma  induced  coagulopathy is caused  by systemic anticoagulation and hyperfibrinolysis 
which occurs due to endothelial injury and protein C activation following hemorrhage from 
trauma sites, fluid replacement, hypothermia and tissue acidosis following  hypo perfusion .(116)  
Some studies have shown that ROTEM analysis was better in comparison to standard 
coagulation tests in diagnosing trauma induced coagulopathy.(117)  In some centers, ROTEM 
analysis is proved  to be useful in diagnosing  Trauma induced coagulopathy  and was used in 
transfusion.(117)  Hyperfibrinolysis associated with trauma   can be diagnosed with the help of 
ROTEM.(118) The A10 variable  correlated with platelet count and fibrinogen concentration  
and detection  help in  earlier goal-directed transfusion therapy and may allow modification  of 
existing transfusion algorithms.(119) 
 
OBSTETRICS 
Postpartum hemorrhage (PPH) associated coagulopathy correlates poorly with standard 
laboratory coagulation tests and ROTEM based algorithms is used for the management of 
specific coagulation deficiencies in these patients. This test is useful in hypofibrinogenemia and 
hyperfibrinolysis .The coagulopathy of PPH is can be due to dilutional, surgical, amniotic fluid 
embolus, and placental abruption causes and the  ROTEM requires nearly 24 hours 
monitoring.(120)A study by Theusinger et al showed that maximum clot firmness in all channels 
were associated with fibrinogen and platelets levels, Clotting time significantly to aPTT and 
maximum clot firmness significantly to fibrinogen. Factor VIII also co related well with all 
ROTEM parameters except with Clotting time and Clot formation time. (121) 
 
LIVER TRANSPLANTATION 
In orthotopic liver transplantation, intraoperative bleeding is a major problem. The underlying 
liver pathology, the replacement of large blood losses, and the altered metabolism of coagulation  
factors during the prehepatic, anhepatic, and neohepatic phases of liver transplantation create a 
complicated hemostatic environment.(98) ROTEM assays can differentiate hypofibrinogenemia 
from thrombocytopenia  based on the channels used.(122) A study by Blasi et al concluded that  
clot thickness at 10 minutes can be used to taken decisions regarding transfusions.(123) 
Recent studies suggest ROTEM diagnose trauma induced coagulopathy more precisely and 
faster than standard coagulation tests. These assays can be used to take decisions regarding 
transfusion therapy as per the patient needs. This approach can therefore   reduce  the risk  of 
over or under transfusion.(124) In comparison with standard coagulation tests, ROTEM
 
parameters precisely detect trauma induced coagulopathy. The critical thresholds defined by 
ROTEM
 
assays in bleeding patients were closely related with mortality and need for early RBC 
transfusion. Low maximum clot firmness  is as an important deciding factor regarding  red cell 
transfusion.(125)  
The most important pathology in poly trauma patients are fibrinogen deficiency, poor fibrinogen 
polymerization and hyperfibrinolysis. A study by Tauber et al showed that when compared with 
standard coagulation profile, ROTEM parametersdetects trauma induced coagulopathy.  The 
results can be obtained within a short time and reflects the in vivo situation in poly trauma 
patients. These patients predominantly showed hypofibrinoginemia and defective fibrin 
polymerization. In this study they found that a Maximum Clot Firmness of less than 7 mm, 
corresponds to a fibrinogen level of less than 150 mg/dl and those subjects had a higher 
mortality. Prothrombin time, fibrinogen concentrations and platelet count co- related with MCF. 
There was a high mortality rate for hyperfibrinolysis in this study, it and this can be reduced by 
early administration of tranexamic acid.
 
 (126) 
 
OTHER CLINICAL CONDITIONS 
Thromboelastometry can be also be used for diagnosis of pronounced hyperfibrinolysis. (127)  
Another study by Raza et al have shown that ROTEM is insensitive until fibrinolytic activity  
reaches a certain threshold but the addition of aprotinin, a stoichiometric inhibitor of plasmin in 
the APTEM assay  have improved  detection of hyperfibrinolysis. (128) Massive hemorrhage is a 
leading cause of mortality after cardiovascular surgery. The standard coagulation tests require a 
long turnaround time and cannot detect multiple hemostatic abnormalities. In a study by 
Sartorius et al  in cardiothoracic surgical patients , clot firmness and maximum amplitude have 
been found to best correlate with platelet function and fibrinogen levels.(129) .When compared 
to standard coagulation tests, ROTEM can assess rate and quality of clot formation. This test is 
performed in whole blood  and assess the collective effect of circulating platelets, RBC, 
leukocytes on clot formation, including platelet function  (130) 
A study by Mittermayr et al used Thromboelastometry heparin-protamine management. The 
variable used was  CT. The ratio of CT in INTEM channel to CT-HEPTEM channel was used to 
differentiate the effects of heparin excess from those of protamine excess. When the ratio was 
more than 1 it is due to excess heparin while ratio equal to 1 was due to excess protamine.(131) 
 
Graphical presentations in various clinical conditions 
 
 
                                                           
                                                            Figure 7 - A normal thromboelastogram 
                                                  
               Figure 8 – Thromboelastogram with prolonged CFT and decreased MCF 
                                                                                 
                 Figure 9 – Thromboelastogram with prolonged CT,CFT and                          
decreased MCF and alpha angle  
 
 
 
                                                  
                                                 Figure 10 – Thromboelastogram with shortened CT and CFT  
 
 
                                                           
 
                                                       
Figure 11-Thromboelastogram with prolonged CFT and decreased 
MCF and alpha angle                                                                   
                                                                                      
                                    
                                                       
                                               Figure 12 – Thromboelastogram with prolonged CT, CFT, 
decreased MCF and alpha angle as in severe coagulopathy 
   
 MATERIALS AND METHODS 
 
This was a prospective study of patients who presented with acquired bleeding disorders in 
Christian Medical College, Vellore. The study was conducted on seventy newly  admitted  
consecutive  bleeding patients  in  the  wards, the emergency and intensive care  units of  
Christian Medical College Hospital for  a period of  two years from 01 January 2013.  A detailed  
history, diagnosis, complete blood count profile, transfusion requirements, condition at discharge  
were collected  with the  help of a prepared pro forma. 
STUDY POPULATION 
 
TEST SAMPLES  
Seventy patient samples of acquired bleeding disorder cases received in the Special Test 
Laboratory, Department of Transfusion Medicine and Immuno hematology   between  January 
2013 – August, 2014 that have shown abnormal coagulation profile were considered as the test 
samples.  The samples were collected on the basis of requests for blood products received in the 
blood bank from emergency, intensive care units and all surgical/ medical including super 
specialty departments. The complete bleeding history was taken from the treating 
physician/surgeon. Samples for the tests were obtained before transfusing the blood products.  
CONTROL SAMPLES 
In our hospital, the Department of Transfusion Medicine and Immuno hematology manages 
the Clinical Pathology Lab, Blood Bank, HLA lab and Special Test Lab for Coagulation work 
up. Patients who are referred from outside hospitals and out patients from other clinical 
departments who had presented with minor bleeding symptoms in the past that did not require 
any medical , surgical or transfusion interventions  or no bleeding symptoms  and had come for 
complete coagulation work up in Special test Lab  were  selected as the control group. On the 
basis of a complete coagulation work up, which included, complete blood count profile, standard 
coagulation profile, coagulation factor assays, Ricof levels and Platelet aggregometry studies, 
this category was diagnosed to have a normal coagulation profile. The first 68 consecutive 
samples during the study period were selected as the control samples. 
 
Inclusion criteria:  
Samples with abnormal thromboelastogram. 
Exclusion criteria: 
1. Paediatric cases  – The normal reference range for prothrombin time, activated partial 
thromboplastin time, platelet count and serum fibrinogen levels are different from the 
adult ranges. There are no well defined pediatric reference ranges for rotem variables.  
2. Repeat sample collected within fifteen days  - Interventions like transfusion, 
medication will affect the coagulation parameters especially stable coagulation factors 
like factor XIII and fibrinogen. Cases on medication and those who had received 
transfusion were excluded from the control group. 
Detailed  history  including  type of bleeding with  duration, diagnosis ,  treatment details like  
transfusion support with components, antifibrinolytics, vitamin K,  factor concentrates were  
taken  in  detail. 
 
Setting where data was collected 
Special test lab, Department of Transfusion medicine and Immuno haematology, Christian 
Medical college, Vellore. 
 
Sampling strategy employed 
All consecutive samples with abnormal thromboelastometry within the given time period were 
included as test samples. Consecutively selected 68 samples with normal coagulation profile 
from patients with minor acquired bleeding disorders were considered as controls. Selection was 
dependent on the reference standard which is the coagulation profile. Samples with abnormal 
coagulation profile were considered as cases and normal samples   as controls. Data   was 
collected from participants prospectively (before performing the diagnostic tests)  
 Detailed  history  including  history  of  risk  factors  if  any  was  taken.  It  included  the 
presenting  symptoms  with  duration,  significant  medication  history  especially  antiplatelet 
drugs , vitamin K antagonists were taken. Treatment details like transfusion of blood, platelets, 
fresh frozen plasma, cryoprecipitate, factor concentrates, use of antifibrinolytics like tranexamic 
acid were also taken in detail.  Investigations like Complete Blood Counts, Prothrombin time, 
INR, Activated partial thromboplastin time, Serum Fibrinogen and platelet count were done by 
automated methods using Sysmex machine and Coulter. All samples including cases and 
controls were subjected to thromboelastometric analysis using the ROTEM machine. 
 
 STANDARD OPERATING PROCEDURE  
ROTEM 
 
Purpose   
To check the coagulation state of a blood sample. 
Principle 
 The ROTEM technology is based on a fixed cylindrical cup and a permanently oscillating 
vertical axis. The axis is supported by a high precision ball bearing and oscillates to the left and 
to the right through an angle of 4.75º. The rotation of the axis is driven by a motor that is 
connected to the axis via an elastic spring. For the measurement, a disposable plastic pin with 6 
mm diameter is placed firmly on the axis and the blood sample is filled into a disposable 8 mm 
diameter cup and is then uplifted onto the measurement channel. Hence, the plastic pin is 
immersed into the blood sample. The rotation is detected optically via a mirror plate at the upper 
end of the axis, a diode as light source and a light sensitive sensor (CCD Chip). If no clotting 
takes place, the movement is not obstructed. When a clot is formed and attaches itself between 
pin and cup surfaces, the movement is obstructed. The result is a balance between the spring 
tension and the tension of the clot. As the clot becomes firmer, the rotational amplitude of the 
axis is reduced. 
 
Sample  
Citrated whole blood (platelet rich plasma can also be used) 
Materials: 
Citrated whole blood, Disposable cups and pins, 100-1000µl, 5-40µl pipettes, 0.2M Calcium 
Chloride, Diluted thromboplastin (1/2000), Personnel Protective Equipment (PPE) 
Sample preparation 
Blood Sample: Blood is preferably drawn via a 21G needle directly into vacuette Greiner tube 
containing 3.2% sodium citrate with minimal stasis. The temperature of the sample may 
influence the measurement results. Measure the blood sample directly after sampling. If this is 
not possible, preheat the blood sample for 5-10 min before measurement in the sample 
preheating station of the ROTEM delta. 
Reagent preparation  
Preparation of Tissue factor:  
Dilute 10µl of recombiplastin into 490µl of Imidazole buffer in tube 1. 
Add 50 µl of the contents in tube 1 to 950 µl of Imidazole buffer in tube 2 and mix well. 
Add 500µl of the contents in tube 2 to 500 µl of imidazole buffer in tube 3 and mix well. 
This diluted recombiplastin is used for the processing of a sample on ROTEM. 
 
 
Procedure  
Switch on the ROTEM system. Activate the ROTEM system with the main switch on the back of 
the device. Push the blue on/off button on the right hand side of the instrument. Log in to the 
system. Touch the screen if the screen saver is active. Select user. Enter password Measurement 
module screen will open. 
Measuring Cell Preparation 
Take the cup with the pin in it from the storage box. Push the pin in the cup onto the axis chosen 
for measurement. The status line under the channel is grey by default. In case the axis has been 
moved heavily when attaching the pin, the channel becomes inactive and the status line turns 
blue during the time of initialization. Place the cup with its opening facing upwards into the 
appropriate preheated cup holder. Leave the cup holders always in the temperature controlled 
area. Push and fix the cup in the cup holder using the MC Rod. The cup must fit tightly. Enter 
Patient Data: Touch one of the four channels. In the upper part of the screen entry fields for 
patient data {Patient ID, Patient name (first name, last name, and comment} are displayed. 
Touch the respective entry field. Enter patient data. 
Procedure  
Add 20µl of 0.2M CaCl2 pre warmed cup. Add 30µl of diluted recombiplastin to a separate 
plastic vial. Mix 500µl of well mixed whole blood the tissue factor. Add 320µl of the mixture to 
the CaCl2 and mix well. Place the cup holder onto the measuring position using the guiding rods. 
The cup holder is kept in measuring position by magnets. Press the ―Start manual‖ icon the 
screen. 
 
Interpretation 
During measurement, the large Thromboelastogram is shown at the left upper side of the screen. 
In the upper right part of the screen, the current measurement results of the test parameters are 
shown. 
ROTEM Parameters  
Clotting Time (CT), Clot Formation Time (CFT), Alpha Angle (α ) Maximum Clot Firmness 
(MCF)  and Maximum Lysis (ML)  
 Clotted sample can interfere with the results.  
PROTHROMBIN TIME (PT) 
 
Purpose   
To look  for the overall efficiency of extrinsic pathway of coagulation and monitoring of oral 
anticoagulant therapy. 
Platform   - Sysmex CS 2000i 
Principle  
Clot based assay. This test reflects the overall efficiency of extrinsic system. It is sensitive to 
changes in factor V, VII and X, and less so to factor II. It is also unsuitable for detecting minor 
changes in fibrinogen level but may be abnormal if the fibrinogen level is very low or if there is 
an inhibitor present. The reagent influences the sensitivity of the test and technique used and is 
important to establish a reference range locally. The reagent, contains tissue factor and 
phospholipids. 
Limits of detection  - 5 to 180 Sec 
Primary sample- 
Citrated  Plasma sample. 
Type of container   
Light blue top vacutainer and 1ml mini collect Greiner Vacutte for pediatric purposes. 
Reagents and Materials 
Dade Innovin: product is reconstituted as per product insert/instruction sheet. This reagent 
already contains CaCl2. Patient plasma, control plasmas as required.  
Procedure 
From Main Menu - Press 'Reagent' icon. The reagent carousal and diluent table is displayed. On 
the screen, select one reagent position within a rack. This will be highlighted in blue, then press 
'Change/Add' button. Wait while the carousal is rotating (the led will turn red). Once the carousal 
comes to a stop, the LED will turn green. Now unlock cover and remove the rack. Place the PT 
reagent (Dade Innovin) bottle into the rack with barcodes facing outwards. Use the appropriate 
adapters to keep smaller reagent containers.  
In case of using cups adapters, they are placed so that the flat edge is facing outwards. Place the 
reagent rack back into the reagent table, replace the lid and lock it. A message will appear 
prompting reagent barcode reading. Press 'OK'. The reagent carousal will start running and will 
read the barcodes within the rack selected. Place the samples in the rack with the barcodes 
visible facing the front of the rack.  
Place the rack on the right side of the sample tray ensuring that right edge of the rack is placed 
under guard rail of the sampler. Press 'Start' icon on the main menu. Select the tests to be 
performed from the grey test selection box. The selected tests will be highlighted with a blue dot. 
Press 'OK' button to return to the Order screen. Press 'Save' to confirm the order of the tests. 
Press 'Start' icon to commence the analysis. Input the appropriate rack number when the sampler 
dialogue box appears. 
 To view sample results, press the ' Joblist' icon on the main menu or the taskbar. The Joblist 
screen will be displayed. The status of the test is displayed in the far left hand column. The Test 
results can be viewed by scrolling across the screen using 'backward' and 'forwards' arrows at the 
bottom of the screen. Samples that have not been analyzed will be shown as a 'tick' along with a 
blue pending box. The result for any sample that requires reviewing will have an asterisk next to 
it. The status bar will display a yellow box stating 'Review'. The 'Review' or 'On hold' status will 
provide alerts regarding the flags attached to that particular result. The tests may be put on hold 
if a new lot no. of reagent has been used but not calibrated. The status bar on the left will be clear 
for analysis that has been completed with no errors. The numerical values will be shown under 
the appropriate test column. Any result that has a red Error box attached will display ***.* 
instead of numeric result. They could be due to events such as rinse solution running out, reagent 
depletion, probe crash etc. 
To review and look up errors and flags on sample result: From the Joblist main screen, select the 
sample no. that needs to be reviewed, it will be highlighted blue. Double click the highlighted 
line or click on the browser. The browser screen is displayed. The results in the browser screen 
are sorted into different user definable tabs. To view at result for a particular test, select the 
appropriate tab on the screen The results will be displayed in the order that the graphs have been 
set to appear. If the test you require is not present then scroll using 'up/down' buttons. Double 
click on the Coagulation curve using the mouse or the touch screen, It will display the detailed 
sample screen. Click the red 'Detail' box to display the error message, For HIL errors. The 
system will flag Hemolysis. lcteric and Lipemia are present. If lipemia occurs, the system may 
perform wavelength switch to minimize interference, this occurs without intervention. For both 
hemolysis and icteric samples, sample will need to be visually checked before result is validated. 
To validate the result, close the error dialogue box. Then close the detailed sample joblist screen. 
Press 'Validate' button. 
QC protocol  
A normal control ( pooled normal plasma [PNP]) and an abnormal control plasma ( Coag-path 
from Stago)  is included with every batch of patient plasma tested, or every few hours if testing a 
large number of plasmas throughout the day. Normal  control and abnormal control plasma are 
run  for 10 days and the mean and +/-2SD is calculated . The control values should fall within +/-
2SD. 
Possible interference  
Improper centrifugation, plasma from badly haemolysed blood, highly lipemic sample and blood 
not tested within four hours of collection. 
Result interpretation   
The results are expressed automatically on the ―worklist‖ page as seconds. The results are always 
interpreted with INR (International Normalized Ratio).  
Normal Range. 10 – 12.5 Secs. 
ISI 
INR = Prothrombin Time (PT) of test plasma (sec) 
Mean Normal Prothrombin Time (MNPT) (sec)  
ISI = International Sensitivity Index. 
INR= International normalized ratio. 
Ideally, each laboratory should establish its own Mean Normal Prothrombin Time (MNPT) 
obtained by testing at least 20 normal plasmas in that laboratory’s PT assay, and taking the mean 
PT. Selected instrument specific ISI values are usually provided for each batch of Innovin. 
 Always use the necessary PPE for all procedures done in the laboratory. Consider every 
biological sample as a potential bio hazard. 
   
ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) 
Platform used 
Sysmex CS 2000i  
Purpose 
To rule out overall efficiency of intrinsic and common pathway of  coagulation and monitoring 
of heparin therapy. 
 
 
Principle  
This is a clot based assay which measures the clotting time of the plasma after the activation of 
contact factors but without adding tissue thromboplastin and so indicates the overall efficiency of 
intrinsic pathway. For the activation of contact factors, the plasma is first pre- incubated for a set 
period of time with a contact activator such as Kaolin or elagic acid. During this phase of the 
test, factor XIIa is produced which cleaves factor XI to XIa but coagulation does not proceed 
beyond this in the absence of calcium. After recalcification, F XIa activates factor IX and 
coagulation cascade proceeds. Since these tests are performed on platelet poor plasma a 
standardized phospholipid is included in the reagent. 
Limits of detection   
8 to 180 Sec  
Primary sample 
Citrated Plasma sample. Light blue top vacutainer and 1ml mini collect Greiner Vacutte  for 
pediatric purposes. 
Reagents and Materials: SynthAsil (IL), CaCl2 provided in the APTT reagent kit, Patient plasma, 
control plasmas as required.  
Procedure  
Loading Reagents on-board the CS 2000i analyzer: From Main Menu -  Press 'Reagent' icon. The 
reagent carousal and diluent table is displayed. On the screen, select one reagent position within 
a rack. This will be highlighted in blue, then press'Change/Add' button. Wait while the carousal 
is rotating (the led will turn red). Once the carousal comes to a stop, the LED will turn green. 
Now unlock cover and remove the rack. Place reagent bottles, Synth Asil and CaCl2 into the 
rack with barcodes facing inside. Use the appropriate adapters to keep smaller reagent 
containers. In case of using cups adapters, they are placed so that the flat edge is facing 
outwards. Place the reagent rack back into the reagent table, replace the lid and lock it. A 
message will appear prompting reagent barcode reading. Press 'OK'. The reagent carousal will 
start running and will read the barcodes within the rack selected. Once the barcodes are read the 
reagent screen will appear. The reagents that have been previously read by the analyzer will be 
displayed in its relevant position number with the name of the reagent underneath. A red 
question mark is displayed if the reagent placed in an adapter cannot be identified as there is no 
barcode or non-readable barcode. If the reagent has been previously placed onboard, then 
highlight the red question mark and press' Edit Reagent Info'. Place the cursor inside the reagent 
box and a drop down menu appears. Now select the appropriate reagent from the list. Click on 
the lot number box and select the lot number from selection list. Enter the type of container by 
selecting from the drop down menu. Press 'OK' to save. Place the samples in the rack with the 
barcodes visible facing the front of the rack.2. Place the rack on the right side of the sample tray 
ensuring that right edge of the rack is placed under guard rail of the sampler. lf the rack is in the 
correct position, the barcodes on the samples are facing towards the analyzer. The rack position 
numbers are from l on left to I0 on the right. Press  
'Start' icon on the main menu. If samples are to be entered  manually.  From the main menu, 
select 'Order' icon. Press 'Order Entry' button on the following screen. For the manual entry of 
sample number, use the onscreen keypad or IPU key pad and enter the value in the blue 'sample 
No.' box. Use the 'Edit Sample info' box to amend the faulty entry. Select the tests to be 
performed from the grey test selection box. The selected tests will be highlighted with a blue dot. 
Use the 'up' /' down' keys to move to subsequent sample positions and make the respective 
entries. Press 'OK' button to return to the Order screen. Press 'Save' to confirm the order of the 
tests. Press 'Start' icon to commence the analysis. Input the appropriate rack number when the 
sampler dialogue box appears.  The Test results can be viewed by scrolling across the screen 
using 'backward' and 'forwards' arrows at the bottom of the screen. Samples that have not been 
analyzed will be shown as a 'tick' along with a blue pending box. The result for any sample that 
requires reviewing will have an asterisk next to it. The status bar will display a yellow box 
stating 'Review'. The 'Review' or 'On hold' status will provide alerts regarding the flags attached 
to that particular result. The tests may be put on hold if a new lot no. of reagent has been used 
but not calibrated. The status bar on the left will be clear for analysis that has been completed 
with no errors. The numerical values will be shown under the appropriate test column. Any result 
that has a red Error box attached will display ***.* instead of numeric result. They could be due 
to events such as rinse solution running out, reagent depletion, probe crash etc. the sample no. 
that needs to be reviewed, it will be highlighted blue. Double click the highlighted line or click 
on the browser. The browser screen is displayed. The results in the browser screen are sorted into 
different user definable tabs e.g., _ Routine. factors. Thrombo etc .,To view at result for a 
particular test, select the appropriate tab on the screen. The results will be displayed in the order 
that the graphs have been set to appear. If the test you require is not present then scroll using 
'up/down' buttons. Double click on the Coagulation curve using the mouse or the touch screen, It 
will display the detailed sample screen. Click the red 'Detail' box to display the error message, 
For HIL errors. The system will flag Hemolysis. lcteric and Lipemia are present. If lipemia 
occurs, the system may perform wavelength switch to minimize interference, this occurs without 
intervention. For both hemolysis and icteric samples, sample will need to be visually checked 
before result is validated. To validate the result, close the error dialogue box. Then close the 
detailed sample joblist screen. Press 'Validate' button. 
QC protocol 
A normal control (e.g. pooled normal plasma [PNP]) and an abnormal control plasma (e.g. Coag-
path from Stago) should also be included with every batch of patient plasma tested, or every few 
hours if testing a large number of plasmas throughout the day. Run normal control and abnormal 
control plasma for 10 days and calculate the mean and +/-2SD. The control values should fall 
within +/-2SD. 
Possible interference 
Improper centrifugation of patient sample and badly hemolysed blood may give an artifactual 
coagulation results that do not accurately represent the coagulation status of the patient under 
investigation. Hemolysed blood may suggest a traumatic blood collection and you may need to 
request a repeat sample collection. Blood not tested within four hours of collection. 
Result interpretation: Report APTT results in seconds. As a rough guide the aPTT of normal 
plasma should be 25 to 35 sec. In our lab any value more than the assigned reference range is 
considered as abnormal and needs further evaluation. Always use the necessary PPE for all 
procedures done in the laboratory. All samples must be processed within four hours of collection. 
 Fibrinogen  
 Platform 
CS 2000i  
Purpose 
To estimate the amount  of fibrinogen in citrated plasma sample. 
Principle 
Clot based assay. 
Dilutions of standard normal plasma with known fibrinogen content are prepared in Imidazole 
buffer. The clotting time is measured after the addition of thrombin. A graph of clotting times 
against the fibrinogen concentration is constructed. The clotting time is proportional to the 
concentration of fibrinogen and the 1/10 dilution is taken to represent the value in the standard 
preparation. The test plasma is diluted 1/10 and the result read from the standard line. 
Limits of detection 
30-1400 mg/dL. 
Primary sample  
Citrated  Plasma sample. Light blue top vacutainer and   1ml mini collect Greiner Vacutte for 
pediatric purposes. 
Reagents and Materials  
 Standard or reference plasma  with known fibrinogen concentration. Thrombin > 30 u/ml 
(concentration may vary according to source) Imidazole buffer (glyoxalin) pH 7.35 
Procedure 
From Main Menu - Press 'Reagent' icon. The reagent carousal and diluents table is displayed. On 
the screen, select one reagent position within a rack. This will be highlighted in blue, then press 
Change/Add' button. Wait while the carousal is rotating (the led will turn red). Once the carousal 
comes to a stop, the LED will turn green. Now unlock cover and remove the rack. Place the 
reconstituted Fibrinogen reagent in Reagent table A. Imidazole Buffer in a 5 ml container is to be 
placed in STAT diluent table. Use the appropriate adapters to keep smaller reagent containers. In 
case of using cups adapters, they are placed so that the flat edge is facing outwards. Place the 
reagent rack back into the reagent table, replace the lid and lock it. A message will appear 
prompting reagent barcode reading. Press 'OK'. The reagent carousal will start running and will 
read the barcodes within the rack selected. 
Calibration  
The required reagents and calibrator are loaded on to the CS-2000i analyzer. The calibrators will 
need to be poured into 4ml cups and placed in the reagent table with suitable adapter.Once the 
barcodes of the reagents have been read, the system is ready to run the calibration for the assay 
and generate calibration curve. Click 'Order' icon from the main menu. In the Order screen, 
select the 'Switch Order' button. Select the 'Holder Calib. Curve  Order' box. Click on the 
required 'Gray button' on the bottom of the screen to select the required assay for the calibration 
curve. Once selected, the assay box will have a blue dot in it. A small screen appears, click into 
the top box labeled 'Reagent lot'. Another box titled select reagent lot will appear. Select the 
required lot from drop down list and press 'OK' Select the appropriate lot no. for the current 
calibration. CS analyzer can hold up to 10 separate calibration curve per assay at a time. If no lot 
numbers are available in the drop down box it means that no reagents are registered on the 
reagent table for this particular assay. Click in the 'Lot' box. The screen will show the calibrator 
lots that are available and select the required lot number. Then Click in the 
 'Assay Sheet Value' box and enter the specific calibrator value. Select 'OK'. The Order screen 
will now show a check (\/) mark under the assays that has been selected for calibration. Select 
'Close' button to go back to the main menu screen. Press 'Start' icon. Select the ' Joblist' icon to 
view the status of the calibration curve. Select the 'Calib Curve' icon. The screen will display the 
respective calibration curve. Review and validate the curve. Place the samples in the rack with 
the barcodes visible facing the front of the rack. Place the rack on the right side of the sample 
tray ensuring that right edge of the rack is placed under guard rail of the sampler. If the rack is in 
the correct position, the barcodes on the samples are facing towards the analyzer. The rack 
position numbers are from l on left to 10 on the right. Press 'Start' icon on the main menu. If 
samples are to be entered  manually. From the main menu, select 'Order' icon. Press 'Order Entry' 
button on the following screen. For the manual entry of sample number, use the onscreen keypad 
or IPU key pad and enter the value in the blue 'sample No.' box. Use the 'Edit Sample info' box to 
amend the faulty entry. Select the tests to be performed from the grey test selection box. The 
selected tests will be highlighted with a blue dot. Use the 'up' /' down' keys to move to 
subsequent sample positions and make the respective entries. Press 'OK' button to return to the 
Order screen. Press 'Save' to confirm the order of the tests. Press 'Start' icon to commence the 
analysis.. Input the appropriate rack number when the sampler dialogue box appears. The Test 
results can be viewed by scrolling across the screen using 'backward' and 'forwards' arrows at the 
bottom of the screen. Samples that have not been analyzed will be shown as a 'tick' along with a 
blue pending box. The result for any sample that requires reviewing will have an asterisk next to 
it. The status bar will display a yellow box stating 'Review'. The 'Review' or 'On hold' status will 
provide alerts regarding the flags attached to that particular result. The tests may be put on hold 
if a new lot no. of reagent has been used but not calibrated. The status bar on the left will be clear 
for analysis that has been completed with no errors. The numerical values will be shown under 
the appropriate test column. Any result that has a red Error box attached will display ***.* 
instead of numeric result. They could be due to events such as rinse solution running out, reagent 
depletion, probe crash etc. For both hemolysis and icteric samples, sample will need to be 
visually checked before result is validated. To validate the result, close the error dialogue box. 
Then close the detailed sample joblist screen. Press 'Validate' button. 
 QC protocol 
A normal control (e.g. pooled normal plasma [PNP]) and an abnormal control plasma (e.g. Coag-
path from Stago) should also be included with every batch of patient plasma tested, or every few 
hours if testing a large number of plasmas throughout the day. Run normal control and abnormal 
control plasma for 10 days and calculate the mean and +/-2SD. The control values should fall 
within +/-2SD. 
Possible interference 
 Improper centrifugation of patient sample and badly haemolysed blood may give an artifactual 
coagulation results that do not accurately represent the coagulation status of the patient under 
investigation. Haemolysed blood may suggest a traumatic blood collection and you may need to 
request a repeat sample collection. Blood not tested within four hours of collection. 
Result interpretation 
The normal range should be established locally but is usually close to 150-450mg/ml. For most 
 Clauss techniques, the relationship between clotting time and fibrinogen concentration is linear 
over a limited range of clotting times, typically 10-25 seconds.  For normal test plasma a 1/10 
dilution can be used (automatically).  For lower concentrations, for example 75-150mg/ml the 
plasma should be diluted 1 in 5.  For levels < 75mg/ml, the test plasma should be diluted 1/2.   
For higher levels (> 400mg/ml), the test plasma should be diluted 1/20. These calculations 
correct for the difference in dilution of the test and standard plasma samples. 
Always use the necessary PPE for all procedures done in the laboratory. All samples must be 
processed within four hours of collection. 
 Platelet Count 
 Principle 
 Perform total Platelet count on a Neubauer chamber. 
Primary sample 
 K2EDTA  blood. 
Sample and equipment requirement :  
Platelet diluting fluid, a. 1% formalin, 3% sodium citrate, 1-2 drops brilliant cresyl blue ,Sahali 
pipette ,Whole blood, Microscope (45X),Neubauer chamber 
Procedure  
Mix the blood specimen carefully. Using sahali pipette dilute the blood 1: 100 with platelet 
diluting fluid. Mix well, after 5 mins charge it on a counting chamber. Place the filled chamber 
under petridish with a moist filter paper. Let it stand for 10 to 15 minutes. Place the counting 
chamber carefully on the stage of microscope. Focus the area under 45 X. Keep the condenser 
down, reduce the light by adjust the diaphragm. Platelet will appear like highly refractile particle. 
Count the platelets on the central RBC square or any of the WBC squares. 
 QC protocol:  
Slide count should be done (1 platelet is equal to 15000 in oil immersion field).  Blank count 
should be done to check the platelet diluting fluid.  Platelet count can be done in cell counter to 
check whether they correlate. Duplicate checking. 
Specimen diluted  
IV line, aged and lysed specimen  interfere with the results. 
 Result interpretation 
Platelets = Number of cell counted x dilution factor x depth factor 
                                           Area counted    
              
                =  Number of cell counted x 100 x 10 
                                           1 
  
 
Table -2 . Statistical analysis plan for calculating sensitivity and specificity of Rotational 
Thromboelastometry compared to Standard coagulation profile 
 
Sensitivity = a/a+c                       
Specificity=d/b+d  
A fixed number of cases and controls are sampled between the patients with acquired bleeding 
disordrs and the normal subjects. When controls are easier to obtain, more controls can be 
considered than cases (Janes et al, 2005).  
 
 
           2X2 TABLE FOR 
ANALYSIS 
 
 
STANDARD COAGULATION    
PROFILE 
(GOLD  STANDARD) 
 
 
     TOTAL 
POSITIVE NEGATIVE 
ROTEM  
(TEST) 
POSITIVE A B  a + b 
NEGATIVE C D c + d 
                         
                     Total 
 
a+c 
 
b+d 
 
a+b+c+d 
RESULTS 
We studied a total of 138 samples which included 70 cases and 68 controls from January 2013- 
August 2014.  
Results: 
Total number of patients studied -138 
Cases (altered standard coagulation profile) -70 
Controls (normal coagulation profile) – 68 
 
 
 
Figure 13-  Flow chart of cases and controls category 
 
 
Total number of 
samples 
n=138 
Cases with abnormal 
coagulation profile 
n=70 
Controls with normal 
coagulation profile 
n=68 
 In the seventy cases, certain cases had one, two or  three altered tests( Prothrombin time, 
activated Partial thromboplastin Time, Platelet count and Serum Fibrinogen levels) , but none 
had all the four coagulation parameters altered. 
 
Table 3 -  Distribution of altered coagulation profile parameters 
 
Total number of patients studied - 138 
Number of cases who had an altered complete standard coagulation profile – 70 
Number of control  who had a normal  complete standard coagulation profile- 68 
Number of cases who had  prolonged Prothrombin time – 64 
Number of cases who had  prolonged Activated Partial Thromboplastin Time – 54 
Number of cases who had low platelet count ( less than 1,00,000/cumm) -44 
Number of cases who had low Fibrinogen levels( less than 150 mg/dl)    -35 
 Figure 14 . Flow chart of cases showing altered coagulation profile 
The baseline characteristics of cases and controls are given in table no 4.. The mean age of cases 
was 41.3±16.2 years and that of controls was 33.3 ±13.7 years. Females accounted for 34.3% of 
the cases and 54.4% of the controls (Figure 15). In both cases and control group, a majority of 
cases were seen in the age group 21 -30 years. (Figure 16) 
 
 
  
Characteristic 
 
Total n(%) 
 
Cases                                 
n(%)mean±sd 
         
Controls                                
n(%)mean±sd                                      
 
Total Number 138 70                  68  
Age (years) 37.3 ± 15.5 41.3± 16.2        33.3±13.7  
Gender Male  77(55.8%) 46 (65.7%)        31(45.6%)  
Female 61 (44.2%) 24 (34.3%)       37 (54.4%) 
Table 4 - Baseline Characteristics 
  
 
 
 
  Figure 15-  Sex distribution among cases and controls                 
 
 
Figure 16- Distribution of age in cases and controls 
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 Figure 17- Distribution of bleeding manifestations among cases. 
The bleeding manifestations ranged from minor mucosal bleeds like epistaxis to life threatening 
operative hemorrhages requiring transfusion support. A major proportion of our cases had severe 
intraoperative and postoperative bleeds leading to coagulopathy. Twelve percent of the total 
cases had more than one bleeding manifestation. 
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Figure18 - Graphical representation of medication usage in  cases. 
Among the cases, nearly 52% of the patients were not on any medications that would have 
caused bleeding. Ten percent of the patients were on Heparin for their primary disease, 1% on 
antiplatelet drugs like Aspirin and Clopidogrel while 7% of patients were on both drugs. In the 
control group all 100% were not on any medication which we had kept as an exclusion criteria 
while selecting the donors. 
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 DIAGNOSIS CASES PERCENT 
 ORTHOPTIC  LIVER TRANSPLANATION 5 7 
VIT K DEPENDANT FACTOR DEFICIENCY 1 1 
TRAUMA INDUCED COAGULOPATHY 22 31 
ACQUIRED HAEMOPHILIA A 2 3 
MALIGNANCY ASSOCIATED COAGULOPATHY 12 17 
 LUPUS ANTICOAGULANT 2 3 
SUB ACUTE DIC 1 1 
OTHER FACTOR DEFICENCY 2 3 
SEPSIS ASSOCIATED COAGULOPATHY 6 9 
COAGULOPATHY ASSOCIATED WITH LIVER 
DISEASE 7 10 
COAGULOPATHY ASSOCIATED WITH OBSTETRIC 
CASES 8 12 
COAGULOPATHY ASSOCIATED WITH SNAKE 
BITE 2 3 
 
Table 5-  Clinical diagnosis leading to bleeding in cases 
 
 
 
 
 
 Figure 19- Distribution of diagnosis in cases 
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       Figure 19- Distribution of Haemoglobin among cases and controls 
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           10 
           
                    21 
     
                                           30 
 
         Total 
           
                     70 
    
                                        100.0 
Table 6- Frequency distribution of Hb levels in cases  
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Total n(%) 
 
Cases 
n(%) or mean±sd 
 
Controls 
n(%) or mean±sd 
Total Number 138 70 68 
Hb 10.5 ± 3.4 8.7± 3.1 12.4±2.6 
 
Table 7- Range of Haemoglobin among cases and controls 
 
All the controls had a  normal haemoglobin levels while the cases it was decreased due to the 
bleeding manifestations. A ten percent of the cases had Hb less than 5 mg/dl.  
RANGE (/cumm)    FREQUENCY           PERCENT 
< 50,000       24             34.3 
50,000-1,00,000      20             28.6 
> 1,00,000      26             37.1 
Table 8- Frequency distribution of platelet count in cases 
 
 
 
All the controls had a normal platelet count while the cases it was decreased due to the bleeding 
manifestations. A ten percent of the cases had Hb less than 5 mg/dl. 
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           >12.4 
 
 
 
64 
 
 
 
91.4 
Table 9- Frequency distribution of normal and altered Prothrombin time among cases 
 
 
Out of the seventy cases, six cases had a normal Prothrombin time as compared to the rest sixty 
four which had a prolonged prothrombin time.  
DIAGNOSIS FREQUENCY 
ACQUIRED HAEMOPHILA A 2 
  COAGULOPATHY ASSOCIATED WITH MALIGNANCY 2 
LUPUS ANTICOAGULANT 1 
COAGULOPATHY ASSOCIATED WITH OBSTETRIC 
CASES 
1 
Table 10 – Disorders which had a normal Prothrombin time 
 
Fifty three out of the sixty four cases, the prothrombin time was corrected on addition of normal 
plasma. Eleven cases did not show any correction and the clinical condition associated with this 
scenario is shown in Table 11 
  
DIAGNOSIS                             NUMBER 
Orthoptic  liver transplanation                                  2 
Trauma induced coagulopathy                                  5 
Coagulopathy associated with liver disease                                  2 
Sepsis associated coagulopathy                                  1 
Coagulopathy associated with obstetric cases                                  1 
Table 11- Cases with no correction Of Prothrimbin time 
 
 
Six out of seventy cases had normal INR (range- 0.99- 1.12) corresponding with  the  PT while 
sixty four cases had a higher INR (range 1.16-10).The normal range of aPTT is 25.1 secs - 36.6 
secs. Fifty four out of seventy patients had a prolonged aPTT (range 37.2 secs - more than 2min) 
while sixteen cases had a normal result (Range- 23.9-35.5secs).  
 
 
 
 Figure 20- Pie chart showing the number of bleeders with normal and altered aPTT 
 
23% 
77% 
NORMAL APTT
PROLONGED APTT
  
Five out of fifty four cases, the aPTT was not corrected with normal plasma and the disorders 
which caused the prolongation are shown in table  
 
  
DISORDERS FREQUENCY 
 Trauma induced coagulopathy 1 
Acquired haemophila A 2 
Lupus anticoagulant 1 
Sepsis associated coagulopathy 1 
 
Table 12 – Disorders which had a prolonged aPTT and not corrected with normal plasma 
 
 
 
 
Figure 21- Distribution of serum Fibrinogen among cases and controls    
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All the controls had a normal fibrinogen level, 4.3% of cases had a fibrinogen level of less than 
50 mg/dL. One case out of this group had undetectable fibrinogen. Nineteen patients (27.1 %) 
the levels of fibrinogen were between 51- 100 mg/dl and thirteen patients between 101-150 mg 
/dL. The remaining fifty percent had a normal fibrinogen level in spite of the bleeding episode. 
 
FIBRINOGEN LEVELS(mg/dL) NUMBER PERCENT 
LESS THAN 50 3 4.3 
51-100 19 27.1 
101-150 13 18.6 
>150  35 50 
 
Table 13- Fibrinogen levels in cases 
 
 
 
 
CT VALUES FREQUENCY PERCENT 
NORMAL  54 77.14 
PROLONGED 16 22.86 
 
Table 14- CT values among cases 
 
 
 
Figure 22 - Scatter diagram of MCF against serum fibrinogen levels. 
 
 
The Pearson product-moment correlation coefficient (PMCC) that expresses the strength of the 
linear relationship between Serum fibrinogen and MCF is R= 0.443.  
 
 
Figure 23- Scatter diagram of MCF against platelet count. 
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 The Pearson product-moment correlation coefficient (PMCC) that expresses the strength of the 
linear relationship between Platelet count and MCF  is R= 0.638 
 
 
 
BLOOD PRODUCT                                        MEAN OF PRODUCT USAGE 
   
 
RED CELL TRANSFUSION 
 
 
4.34(0-35) 
    
  
FFP TRANSFUSION 
 
 
5.22(0-51) 
    
 
PLATELET TRANSFUSION 
 
 
6 (0-77) 
     
 
CRYOPRECIPITATE TRANSFUSION 
 
 
9(0-98) 
 
Table 15 - Blood product usage in cases 
 
 
 
 
 
 Figure 24 -Use of  various blood proucts in cases 
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Figure 25 - Frequency of outcome of cases 
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Comparison of coagulopathy 
detection by ROTEM- CLOTTING 
TIME and  PROTHROMBIN TIME 
in Standard coagulation profile 
 
 
PROTHROMBIN TIME 
 
 
 
TOTAL 
 
 
POSITIVE 
 
 
NEGATIVE 
 
ROTEM 
CLOTTING 
TIME 
 
 
 
 
POSITIVE 
 
 
 
 
12 
 
 
 
 
06 
 
 
 
 
18 
 
 
 
NEGATIVE 
 
 
 
52 
 
 
 
62 
 
 
 
114 
 
 
 
 
TOTAL 
 
 
 
 
64 
 
 
 
 
68 
 
 
 
 
132 
Table 16 - Comparison of ROTEM - Clotting Time (CT) with the Prothrombin time (PT) 
 
 
 
The Kappa Statistic for agreement between ROTEM – CT and PT in detection of coagulopathy 
is K = 0.101 (-0.019 to 0.221) indicating a POOR agreement between the ROTEM -CT and PT. 
(p<0.129) 
 
 
 
 
Value of K Strength of agreement Agreement in this study 
<0.20 Poor            ← 
0.21-0.40 Fair  
0.41-0.60 Moderate  
0.61-0.80 Good  
0.81-1.00 Very Good  
Table 17- Interpretation of the Kappa statistic 
 
 
Analyzing the test characteristics of the ROTEM – Clotting Time in comparison to the 
Prothrombin Time: 
 
Sensitivity of the ROTEM- CT compared to the PT= a/a+c=12/64  
                                                                                 = 18.75% (95% C.I. =10.09 % to 30.47 %) 
 
Specificity of the ROTEM – CT compared to the PT = d/b+d =   62/68 
                                                                                     = 91.18% (95% C.I. =81.77 % to 96.67%). 
 
 
 
  
Comparison of coagulopathy 
detection by ROTEM- CLOTTING 
TIME and coagulation profile 
ACTIVATED PARTIAL 
THROMBOPLASTIN TIME 
  
  
 ACTIVATED  PARTIAL 
THROMBOPLASTIN TIME                      
 
    
 
TOTAL 
 
 
POSITIVE 
 
 
NEGATIVE 
 
ROTEM 
CLOTTING  
TIME 
 
 
 
 
POSITIVE 
 
 
 
 
12 
 
 
 
 
05 
 
 
 
 
17 
 
 
 
NEGATIVE 
 
 
 
42 
 
 
 
63 
 
 
 
105 
 
 
 
TOTAL 
 
 
 
54 
 
 
 
68 
 
 
 
122 
Table 18- Comparison of ROTEM Clotting time (CT) with Activated   partial 
thromboplastin time(APTT) 
 
The Kappa Statistic for agreement between CT and APTT in detection of   coagulopathy is  
K =0.160 (0.023-0.297) indicating a   POOR  agreement between the CT and APTT. (p<0.033) 
 
 
 
 
 Value of K Strength of agreement Agreement in this study 
<0.20 Poor             ← 
0.21-0.40 Fair  
0.41-0.60 Moderate  
0.61-0.80 Good  
0.81-1.00 Very Good  
Table 19- Interpretation of the Kappa statistic 
 
Analyzing the test characteristics of the CT in comparison to the APTT: 
Sensitivity of the CT compared to the APTT = a/a+c =12/54 
                                                                           =22.22% (95% C.I. =12.06-35.60) 
Specificity of the CT compared to the APTT = d/b+d = 63/68   
                                                                         =92.65% (95% C.I. =83.66 – 7.54). 
                                                                                                                                                                       
  
 
Comparison of coagulopathy 
detection by ROTEM- CFT and SCP-
PT 
 
 
PROTHROMBIN  TIME 
 
TOTAL 
 
 
POSITIVE 
 
 
NEGATIVE 
 
ROTEM 
CLOT 
FORMATION 
TIME 
 
 
 
 
POSITIVE 
 
 
 
 
27 
 
 
 
 
3 
 
 
 
 
30 
 
 
 
 
NEGATIVE 
 
 
 
 
37 
 
 
 
 
65 
 
 
 
 
102 
 
 
 
 
 
TOTAL 
 
 
 
 
 
64 
 
 
 
 
 
68 
 
 
 
 
 
132 
Table 20- Comparison of ROTEM Clot Formation Time (CFT) with the Prothrombin 
time(PT) 
 
 
The Kappa Statistic for agreement between ROTEM CFT and APTT in detection of  
coagulopathy is K =  0.384 (0.248-0.519)  indicating a  FAIR  agreement between the CFT 
andAPTT . (p<0.000) the sensitvity 
 
Value of K Strength of agreement Agreement in this study 
<0.20 Poor  
0.21-0.40 Fair   ← 
0.41-0.60 Moderate  
0.61-0.80 Good  
0.81-1.00 Very Good  
Table 21- . Interpretation of the Kappa statistic 
 
Analyzing the test characteristics of the ROTEM – CFT in comparison to the APTT: 
Sensitivity of the ROTEM- CFT compared to the APTT = a/a+c = 27/64 
                                                                                          = 42.19% (95% C.I. =29.94-55.18) 
Specificity of the ROTEM- CFT compared to the APTT = d/b+d = 65/68 
                                                                                         = 95.59% (95% C.I. =87.63-99.03). 
 
 
  
 
Comparison of coagulopathy 
detection by ROTEM- CLOT 
FORMATION TIME  and 
ACTIVATED PARTIAL 
THROMBOPLASTIN TIME 
 
 
ACTIVATED PARTIAL 
THROMBOPLASTIN TIME 
 
 
 
 
 
 
 
 
TOTAL 
 
 
 
POSITIVE 
 
 
 
NEGATIVE 
 
 
 
ROTEM- CLOT 
FORMATION 
TIME 
 
 
 
 
POSITIVE 
 
 
 
 
24 
 
 
 
 
3 
 
 
 
 
27 
 
 
 
 
NEGATIVE 
 
 
 
 
30 
 
 
 
 
65 
 
 
 
 
95 
 
 
 
 
TOTAL 
 
 
 
 
54 
 
 
 
 
68 
 
 
 
 
122 
Table 22- Comparison of ROTEM Clot Formation Time  with the activated Partial 
Thromboplastin Time 
 
The Kappa Statistic for agreement between ROTEM CFT and  APTT in detection of  
coagulopathy is K =0.422(0.275-0.570) indicating a  MODERATE agreement between the two-
cell and three-cell panels. (p<0.000) 
 
 
 
 Value of K Strength of agreement Agreement in this study 
<0.20 Poor  
0.21-0.40 Fair  
0.41-0.60 Moderate ← 
0.61-0.80 Good  
0.81-1.00 Very Good  
Table  23-  Interpretation of the Kappa statistic 
 
Analyzing the test characteristics of the ROTEM- CFT in comparison to the APTT : 
Sensitivity of the CFT compared to the APTT= a/a+c =24/54  
                                                                          = 44.44% (95% C.I. =30.92 -58.60.) 
Specificity of the CFT compared to the APTT= d/b+d = 65/68  
                                                                          = 95.59.% (95% C.I. =87.63 -99.03). 
 
. 
 
 
 
Comparison of coagulopathy 
detection by ROTEM- CLOT 
FORMATION TIME  and 
PLATELET COUNT -Standard 
coagulation profile 
 
 
PLATELET COUNT 
 
 
 
 
 
TOTAL 
 
 
 
POSITIVE 
 
 
 
NEGATIVE 
 
ROTEM- CLOT 
FORMATION 
TIME 
 
 
 
 
POSITIVE 
 
 
 
 
20 
 
 
 
 
3 
 
 
 
 
23 
 
 
 
NEGATIVE 
 
 
 
24 
 
 
 
65 
 
 
 
89 
 
 
 
 
TOTAL 
 
 
 
 
44 
 
 
 
 
68 
 
 
 
 
112 
Table 24- Comparison of ROTEM CFT with the PLATELET COUNT 
 
The Kappa Statistic for agreement between ROTEM CFT and PLATELET COUNT in detection 
of  coagulopathy is K =  0.448 (0.268-0.538) indicating a MODERATE  agreement between the  
CFT and PC (p<0.000) 
 
 
 
 Value of K Strength of agreement Agreement in this study 
<0.20 Poor  
0.21-0.40 Fair  
0.41-0.60 Moderate            ← 
0.61-0.80 Good  
0.81-1.00 Very Good  
Table 25 -Interpretation of the Kappa statistic 
 
Analyzing the test characteristics of the ROTEM CFT  in comparison to the PC: 
Sensitivity of the ROTEM- CFT compared to the PC = a/a+c =20/44 
                                                                                     = 45.5% (95% C.I. =35.4-50.4) 
Specificity of the ROTEM CFT compared to the PC = d/b+d = 65/68 
                                                                                       = 95.59.% (95% C.I. =87.63-99.03). 
 
 
 
  
Comparison of coagulopathy 
detection by ROTEM Clot Formation 
Time and FIBRINOGEN 
 
 
FIBRINOGEN 
 
 
 
 
TOTAL 
 
 
 
 
POSITIVE 
 
 
 
 
NEGATIVE 
 
ROTEM- CFT 
 
 
POSITIVE 
 
 
16 
 
 
3 
 
 
19 
 
 
 
 
NEGATIVE 
 
 
 
 
19 
 
 
 
 
65 
 
 
 
 
84 
 
 
 
 
TOTAL 
 
 
 
 
35 
 
 
 
 
68 
 
 
 
 
103 
Table 26- Comparison of ROTEM CFT with the FIBRINOGEN. 
 
The Kappa Statistic for agreement between ROTEM CFT and SCP FIBRINOGEN in detection 
of coagulopathy is K = 0.465  (0.286-0.644) indicating a MODERATE   agreement between the 
CFT AND FIBRINOGEN . (p<0.000) 
 
 
 
 Value of K Strength of agreement Agreement in this study 
<0.20 Poor  
0.21-0.40 Fair  
0.41-0.60 Moderate            ← 
0.61-0.80 Good  
0.81-1.00 Very Good  
Table 27-   Interpretation of the Kappa statistic 
 
Analyzing the test characteristics of the ROTEM CFT in comparison to the FIBRINOGEN  
 
Sensitivity of the ROTEM- CFT compared to the   FIBRINOGEN = a/a+c =16/35 
 
                                                                                                 =45.71% (95% C.I. =28.84-63.35) 
 
Specificity of the ROTEM- CFT compared to the FIBRINOGEN = d/b+d =   65/68  
                                                                                               = 95.59% (95% C.I. =87.63-99.03). 
 
 
  
Comparison of coagulopathy 
detection by ROTEM AA and 
PLATELET COUNT Standard 
coagulation profile 
 
PLATELET COUNT 
 
TOTAL 
 
 
POSITIVE 
 
 
NEGATIVE 
 
ROTEM 
ALPHA ANGLE 
 
 
 
 
 
POSITIVE 
 
 
 
 
 
23 
 
 
 
 
 
1 
 
 
 
 
 
24 
 
 
 
 
NEGATIVE 
 
 
 
 
21 
 
 
 
 
67 
 
 
 
 
88 
 
 
 
 
 
TOTAL 
 
 
 
 
 
44 
 
 
 
 
 
68 
 
 
 
 
 
112 
Table 28- Comparison of ROTEM AA with the PC 
 
The Kappa Statistic for agreement between ROTEM AA and PC .in detection of   coagulopathy 
is K = 0.552  (36.69 -67.53) indicating a MODERATE agreement between the two-cell and 
three-cell panels. (p<0.000.)  
 
 
  
Value of K Strength of agreement Agreement in this study 
<0.20 Poor  
0.21-0.40 Fair  
0.41-0.60 Moderate ← 
0.61-0.80 Good  
0.81-1.00 Very Good  
Table 29- Interpretation of the Kappa statistic 
 
Analyzing the test characteristics of the ROTEM in comparison to the SCP: 
Sensitivity of the ROTEM AA   compared to the  PC = a/a+c =23/44 
                                                                                     =52.27 % (95% C.I. =36.69-67.53) 
Specificity of the ROTEM AA compared to the PC = d/b+d = 67/68  
                                                                                    = 98.53.% (95% C.I. =92.05-99.75). 
 
 
 
  
 
 
Comparison of coagulopathy 
detection by ROTEM Alpha angle 
and Fibrinogen 
 
 
FIBRINOGEN 
 
 
 
 
 
 
 
TOTAL 
 
 
POSITIVE 
 
 
NEGATIVE 
 
ROTEM 
ALPHA ANGLE 
 
 
 
 
 
POSITIVE 
 
 
 
 
 
13 
 
 
 
 
 
1 
 
 
 
 
 
14 
 
 
 
NEGATIVE 
 
 
 
22 
 
 
 
67 
 
 
 
89 
 
 
 
 
 
TOTAL 
 
 
 
 
 
35 
 
 
 
 
 
68 
 
 
 
 
 
103 
Table 30- Comparison of ROTEM AA with the FIBRINOGEN. 
 
 
 
The Kappa Statistic for agreement between ROTEM -AA and   FIBRINOGEN in detection of  
coagulopathy is K =0.418(0.242 -0.593) indicating a MODERATE  agreement between AA 
AND FIBRINOGEN . (p<0.000) 
 
 
  
 
Value of K Strength of agreement Agreement in this study 
<0.20 Poor  
0.21-0.40 Fair  
0.41-0.60 Moderate ← 
0.61-0.80 Good  
0.81-1.00 Very Good  
Table 31- Interpretation of the Kappa statistic 
 
Analyzing the test characteristics of the ROTEM AA in comparison to the FIBRINOGEN : 
Sensitivity of the ROTEM AA compared to the FIBRINOGEN = a/a+c =13/35 
                                                                                                =37.14% (95% C.I. =21.49-55.07%) 
Specificity of the ROTEM AA compared to the FIBRINOGEN = d/b+d= 67/68 
                                                                                                 = 98.53% (95% C.I. =92.05-99.75).                                                                                                                                                                          
 
 
  
 
 
 
Comparison of coagulopathy 
detection by ROTEM MCF  and PC 
 
PLATELET COUNT 
 
 
 
 
TOTAL  
 
POSITIVE 
 
 
NEGATIVE 
 
ROTEM 
MAXIMUM 
CLOT 
FIRMNESS 
 
 
 
 
 
POSITIVE 
 
 
 
 
 
38 
 
 
 
 
 
5 
 
 
 
 
 
43 
 
 
 
 
 
 
NEGATIVE 
 
 
 
 
 
 
6 
 
 
 
 
 
 
63 
 
 
 
 
 
 
69 
 
 
 
 
TOTAL 
 
 
 
 
44 
 
 
 
 
68 
 
 
 
 
112 
Table 32 - Comparison of ROTEM MCF with the PC 
 
 
The Kappa Statistic for agreement between ROTEM MCF and PC in detection of coagulopathy 
is K =0.793 (0.677-0.909) indicating a GOOD agreement between the MCF AND PC. (p<0.000) 
 
 
  
Value of K Strength of agreement Agreement in this study 
<0.20 Poor  
0.21-0.40 Fair  
0.41-0.60 Moderate  
0.61-0.80 Good                        ← 
0.81-1.00 Very Good  
Table 33- Interpretation of the Kappa statistic 
 
 
Analyzing the test characteristics of the ROTEM MCF in comparison to the Platelet count : 
 
Sensitivity of the ROTEM MCF compared to the Platelet count = a/a+c =38/44 
                                                                                     =86.36% (95% C.I. =72.64-94.79) 
 
Specificity of the ROTEM MCF compared to the Platelet count = d/b+d = 63/68  
                                                                                    = 92.65% (95% C.I. =83.66-97.54.). 
 
  
 
Comparison of coagulopathy 
detection by ROTEM  MCF and 
FIBRINOGEN 
 
 
FIBRINOGEN 
 
 
 
TOTAL 
 
 
POSITIVE 
 
 
NEGATIVE 
 
ROTEM 
MAXIMUM 
CLOT 
FIRMNESS 
 
 
 
POSITIVE 
 
 
 
31 
 
 
 
5 
 
 
 
36 
 
 
 
NEGATIVE 
 
 
 
4 
 
 
 
63 
 
 
 
67 
 
 
 
 
TOTAL 
 
 
 
 
35 
 
 
 
 
68 
 
 
 
 
103 
Table 34- Comparison of ROTEM MCF with the FIBRINOGEN 
 
 
The Kappa Statistic for agreement between ROTEM MCF and FIBRINOGEN.in detection of 
coagulopathy is K = 0.807 (0.686 -0.927) indicating a VERY GOOD agreement between the 
two-cell and three-cell panels. (p<0.000) 
 
 
 
  
Value of K Strength of agreement Agreement in this study 
<0.20 Poor  
0.21-0.40 Fair  
0.41-0.60 Moderate  
0.61-0.80 Good  
0.81-1.00 Very Good ← 
Table 35- Interpretation of the Kappa statistic 
 
 
Analyzing the test characteristics of the ROTEM MCF in comparison to the FIBRINOGEN : 
 
Sensitivity of the ROTEM MCF compared to the   FIBRINOGEN = a/a+c =31/35 
                                                                                             = 88.57 % (95% C.I. = 73.24-96.73%) 
Specificity of the ROTEM MCF compared to the FIBRINOGEN = d/b+d = 63/68 
                                                                                              = 92.65% (95% C.I. =83.66-97.54). 
 ROTEM COAGULATION  
PROFILE 
K  
value 
Correlation  Sensitivity Specificity 
Clotting 
Time 
Prothrombin Time 0.101 POOR 18.8% 91.2% 
Clotting 
Time 
Activated Partial 
Thromboplastin 
Time 
0.160 POOR 22.2% 92.7% 
Clot 
Formation 
Time 
Prothrombin Time 0.384 FAIR 42.2% 95.6% 
Clot 
Formation 
Time 
Activated Partial 
Thromboplastin 
Time 
0.422 MODERATE 44.4% 95.6% 
Clot 
Formation 
Time 
Platelets 0.404 MODERATE 45.5% 95.6% 
Clot 
Formation 
Time 
Fibrinogen 0.465 MODERATE 45.7% 95.6% 
Alpha 
Angle 
Platelets 0.552 MODERATE 52.3% 98.5% 
Alpha 
Angle 
Fibrinogen 0.418 MODERATE 37.1% 98.5% 
Maximum 
Clot 
Firmness 
Platelets 0.793 GOOD 86.3% 92.7% 
Maximum 
Clot 
Firmness 
Fibrinogen 0.807 VERY GOOD 88.6% 92.7% 
Table 36- Corelation between Rotem parameters and Standard coagulation profile 
 
DISCUSSION: 
The management of acquired bleeding disorders depends on the clinical diagnosis that causes the 
bleeding disorder. In our institution any patient admitted with traumatic injury, severe blood loss, 
coagulopathies of any cause are given blood product support. The blood bank doctor or the 
clinical hematologist is informed regarding patients clinical condition, who suggests the 
necessary blood product to be transfused. The samples are drawn for preliminary investigations 
which include the standard coagulation tests and complete blood counts. The transfusion therapy 
is given empirically, starting with cryoprecipitate followed by other products like red cell 
concentrate, fresh frozen plasma and platelets. Further transfusion requirements are based on the 
coagulation parameters of the patient, the results of which take about 45 minutes to be available 
online. In case of postoperative bleeding in cardio thoracic and liver transplant cases, 
coagulopathy monitoring is done by standard coagulation tests and thromboelastometry, as per 
the surgeons request. 
Our study aimed to compare the thromboelastometry method to standard coagulation profile in 
detecting coagulopathies. The current study is a diagnostic study   and included 70 patients with 
acquired bleeding disorders and 68 controls who had normal coagulation profile. In all samples 
the standard coagulation tests (gold standard) and thromboelastometry were performed. 
The role of thromboelastometry in assessing coagulopathy has not been extensively studied in 
India.  There are several observational studies  showing poor correlation between Prothrombin 
Time and activated Partial Thromboplastin Time  to Clotting Time , a good correlation between 
Prothrombin Time and activated Partial Thromboplastin Time to Clot Formation Time, and a 
very good correlation between Fibrinogen level and Maximum Clot Firmness (132)  Platelet 
count and fibrinogen levels correlated significantly with clot strength, and fibrinogen levels 
correlated with fibrin polymerization.(133)  A significant correlation was found between 
activated partial thromboplastin time and Clot Formation Time. 
A total of 138 cases were included in this study. The mean age of males in the case group was 44 
years and that of female patients were 36 years while in control group was 36 years and 31 years   
for men and women respectively. The mean age of all patients in the study group was 37 years. 
The reference ranges for standard coagulation profile and ROTEM variables differ in children 
and so pediatric bleeding cases were not taken up for the study. 
From our study we found that ROTEM MCF and Fibrinogen has a very good agreement K = 
0.807 (p<0.000) with 88.6% of cases showing a decreased maximum clot firmness. Similar 
results were obtained by a study done by Tauber et al. (126) We evaluated the cases with 
fibrinogen levels less than 150 mg/dl as this was considered as a threshold of cryoprecipitate 
transfusion in our institution. The fibrinogen levels ranged from undetectable levels to 148.9 
mg/d.  The clinical conditions which led to decreased fibrinogen levels that correlated well with 
MCF values were coagulopathy due to trauma and obstetric causes. There are several studies on 
obstetric conditions leading to coagulopathy and diagnosis on the basis of 
thromboelastometry.(120) The sensitivity and specificity were high, 88.57 % and 92.65% . 
Severe depletion of plasma fibrinogen levels below 1.0 g /liter were observed in 63%.  
ROTEM   maximum clot firmness and platelet count has a GOOD agreement K =0.793 (0.677-
0.909) indicating a good agreement between the Maximum clot firmness and platelet count 
(p<0.000). The sensitivity was 86.36% and specificity 92.65%. The platelet count of these 44 
patients ranged from 6000/cumm to 96,000/cumm. This finding was similar to data from liver 
transplantation in adults, where thromboelastometry was used to assess the coagulation 
status(135) Thus, MCF values might serve as surrogate parameters to estimate platelet function. 
There was a moderate response in the following correlations  
1. Clot formation time and activated partial thromboplastin time 
2. Clot formation time and  platelet count 
3. Clot formation time and  fibrinogen 
4. Alpha angle and platelet count 
5. Alpha angle and fibrinogen. 
 Clot formation time and activated partial thromboplastin time 
Out of the 54 cases who had a prolonged aPTT , only 24 cases  showed prolonged clot formation 
times giving a sensitivity of 44.44%, while in the control group  only three presented with a 
prolonged clot formation time, thereby giving a specificity of 95.59 %. The kappa statistic for 
agreement was 0.422, p<0.000. This is in contrast to a study by Haas et al and Rugeri et al which 
showed higher correlation between of activated partial thromboplastin time (aPTT) and CFT 
(132,135) 
Clot formation time and  platelet count, fibrinogen  
Out of the 44 cases who had a platelet count less than one lakh, only 20 cases had prolonged clot 
formation times (sensitivity - 45.5%), while in the control group only three presented with a 
prolonged clot formation time, thereby giving a specificity of 95.6 %. The kappa statistic for 
agreement was 0.448, p<0.000. CFT and fibrinogen gave a moderate correlation and had a 
sensitivity of only 45.71% while the specificity was high. There has not been much studies on 
Clot formation time and platelet count and fibrinogen. 
Alpha angle and platelet count 
Out of the 44 cases who had a platelet count less than one lakh, only 23 cases had a decreased 
alpha angle (sensitivity – 52.3%), while in the control group only one presented with a decreased 
alpha angle, thereby giving a specificity of 98.5 %. The kappa statistic for agreement was 0.552, 
p<0.000. A study by Theusinger et al showed that there is a significant correlation between alpha 
angle and platelets.(121) Alpha angle takes into account the functional ability of platelets in 
addition to the platelet count. Therefore in alpha angles will be normal when the counts are low 
and when the platelet function is good. 
Alpha angle and fibrinogen  
The alpha angle gave a moderate correlation with the Fibrinogen, k = 0.418, while studies have 
shown that there is  a good correlation between alpha angle and fibrinogen.(121) 
CT and PT 
 There is a poor correlation between Clotting Time and Prothrombin Time in this study. This is 
contradictory to the study by Haas et al where there was good correlation between PT and 
CT.(132) 
CT and APTT 
There is a poor correlation between Clotting Time and Prothrombin Time and Clotting Time and 
APTT. Study by Haas at showed   a high correlation to the CFT and aPTT which was 
contradictory to our findings. (132) 
LIMITATIONS 
 
Predictive values could not be ascertained because it is not a prevalence study.  
The data was analyzed in the binary or dichotomous mode which could have been processed in 
the ordinal mode. 
We were not able to correlate maximum lysis with any factor, since all patients did not have a D 
Dimer or factor XIII levels done. 
We could only collect the correct sample size for  cases with low fibrinogen levels whereas in 
other cases we had  sample size more than that was required for this type of study which was 
calculated on the basis of literature reviews and pilot studies done earlier in the department.  
 
 
 
 
 
 
 
 
                                                                                                                                                                       
 
CONCLUSIONS 
The achievement of hemostasis   is a crucial factor for determining patient outcomes in acquired 
bleeding disorders. The   standard coagulation tests are still the gold standard for the diagnosis of 
acquired coagulation factor deficiencies.  These tests are designed in such a way that it is 
incapable of representing the balance of coagulation, as it is an in vitro test. Rotational 
Thromboelastometry analysis can be performed as bedside tests but standard coagulation profile 
can be done in a central laboratory and this can cause a delay for sample transport. The 
turnaround time for standard coagulation tests are long (average- 45 minutes) compared to the 
earlier results of thromboelastometry which are obtained within ten minutes.  Therefore 
thromboelastometry can be used as a screening method for detecting thrombocytopenia and 
hypofibrinogenemia in hemorrhagic conditions and can help in early transfusion support of these 
patients. 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
1. PT- Prothrombin time 
2. APTT-Activated Partial Thromboplastin Time 
3. INR- International Normalized Ratio 
4. PC-Platelet Count 
5. CT-Clotting Time 
6. CFT-Clot Formation Time 
7. AA- Alpha Angle 
8. MCF- MaximumClot Firmness 
9. ML-Maximum Lysis 
10. DIC-Disseminated Intravascular Coagulation 
11. TPAI-Tissue Plasminogen Activator Inhibitor 
12. SCP-Standard Coagulation Profile 
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Data entry form  
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 Data Excel sheets – Cases, Controls and Codes 
 
SL NO UIN AGE GENDER BLEEDING  DISORDER MEDICATIONS DIAGNOSIS Hb Platelet Count PT PT- C INR APTT APTT-C FIBRINOGEN CT CFT alpha angle MCF ML RC PRC FFP Cryoppt OUTCOMES Date of test Last date of review
1 B01 62 0 10 0 1 11.2 57,000 16.4 12.1 1.47 60.5 31.3 106.3 276 385 43 35 1 3 8 8 22 1 26.08.2013 09.11.2013
2 B02 41 1 18 0 6 9.3 2,44,000 11.5 0 1.05 72.8 58.2 327 687 110 70 69 14 0 0 0 0 2 20.02.2013 25.02.2013
3 B03 52 0 24 0 2 3.4 2,85,000 120 11.5 10 180 26.9 502.8 1340 4061 8 4 1 5 3 10 0 2 01.06.2013 06.06.2013
4 B04 45 0 15 3 13 10.7 68,000 12.8 11.6 1.16 26.2 0 96 246 152 62 50 13 0 0 0 0 2 02.08.2013 14.08.2013
5 B05 30 0 4 0 4 14.1 2,17,000 10.8 0 0.99 59 30.5 349.1 704 172 58 58 7 0 0 2 0 5 05.08.2013 05.08.2013
6 B06 43 0 9 0 5 4.4 67,000 14 11.8 1.28 29.4 0 596 326 207 54 69 1 4 0 0 0 1 15.03.2013 22.03.2013
7 B07 26 1 10 0 11 7.6 96,000 16.5 11.8 1.48 61.2 28.5 78.2 204 142 67 53 2 7 4 4 12 2 28.08.2013 01.09.2013
8 B08 61 0 10 0 3 7.1 1,12,000 17 11.8 1.53 107.2 30.7 203.8 418 150 61 55 4 4 0 8 6 4 04.09.2013 07.09.2013
9 B09 20 0 24 0 3 3.4 96,000 21 12.1 1.86 93.3 51.4 78.9 552 190 57 45 1 35 13 51 30 4 09.09.2013 12.09.2013
10 B10 58 1 6 0 3 9.9 2,10,000 34.5 12.6 2.99 47.4 27.6 450.4 467 220 56 79 1 2 0 4 0 4 25.09.2013 28.09.2013
11 B11 63 0 19 0 12 5.6 52,000 16.6 12.1 1.49 35.5 0 108.1 295 112 69 57 1 5 0 8 24 1 24.10.2013 26.10.2013
12 B12 22 1 20 0 5 11.1 15,000 12.4 0 1.12 48.4 28.3 165.9 468 1231 19 25 2 7 46 16 79 1 03.08.2014 30.08.2014
13 B13 45 0 10 4 1 13.6 77,000 16.6 12.2 1.52 61.4 32.4 104.6 237 195 58 46 7 1 0 9 16 1 26.06.2014 15.07.2014
14 B14 52 1 11 0 6 11.5 4,36,000 16.1 11.4 1.43 43.3 30.7 222.4 403 116 67 64 11 0 0 0 0 5 12.07.2013 12.07.2013
15 B15 18 0 2 0 10 4 69,000 14.8 11.8 1.32 49.4 35.2 152.7 570 1188 26 4 1 0 0 0 0 5 14.12.2013 14.12.2013
16 B16 45 0 2 0 5 10.5 38,000 14.5 12.1 1.3 28.4 0 180.2 629 390 10 18 4 10 28 16 6 1 18.01.2014 12.02.2014
17 B17 58 1 21 0 7 12.2 71,000 14.6 11.4 1.3 47.7 31.3 107.4 459 187 57 45 12 0 0 0 0 5 06.01.2014 06.01.2014
18 B18 23 0 1 3 10 12.4 2,82,000 15.2 11.7 1.39 39.1 29.5 77.1 342 252 54 43 8 1 0 4 5 3 14.02.2014 23.02.2014
19 B19 54 0 6 0 5 8.2 33,000 14.2 11.5 1.27 43.5 32.4 560.5 473 106 70 59 34 0 0 0 0 5 09.01.2014 10.01.2014
20 B20 32 0 10 4 3 7.7 1,16,000 18 12.2 1.64 49.7 34.2 213.7 493 112 67 55 7 4 0 4 7 1 14.03.2014 05.05.2014
21 B21 19 0 3 0 5 7 6,000 22.5 12.35 2.06 48.9 28.6 92.9 593 202 19 16 5 0 2 4 6 1 24.03.2014 10.04.2014
22 B22 25 1 16 3 5 8.7 62,000 13.3 11.8 1.21 27.3 0 280.6 412 168 58 53 5 3 6 0 0 1 01.04.2014 04.04.2014
23 B23 40 0 22 0 5 6 7,000 12.1 0 1.1 42.1 25.1 306.9 768 220 21 10 2 13 77 24 0 4 04.04.2014 19.04.2014
24 B24 61 1 16 3 5 5.4 17,000 15 12 1.37 23.9 0 218.2 513 186 16 11 7 3 5 22 5 4 05.04.2014 10.04.2014
25 B25 31 1 9 0 3 7.1 3,77,000 16.9 11.9 1.54 88.3 39.6 243.4 531 115 69 71 4 2 0 0 0 1 07.04.2014 08.04.2014
26 B26 68 0 1 0 4 10.7 29,000 12.2 0 1.11 133.3 38.8 284 2209 3 8 14 1 0 0 0 0 5 11.04.2014 11.04.2014
27 B27 37 0 12 3 3 9.6 1,51,000 15.9 12.1 1.45 58.7 29.2 52.1 232 237 50 51 1 2 2 4 0 2 23.04.2014 05.05.2014
28 B28 43 1 3 0 5 9.7 59,000 13 11.8 1.18 28.6 0 254.9 435 232 50 45 4 3 6 20 23 1 23.04.2014 09.05.2014
29 B29 52 0 10 3 3 8.4 72,000 14.2 11.6 1.29 41.4 26 165.2 331 111 68 59 8 12 3 0 6 2 03.05.2014 29.05.2014
30 B30 32 1 23 0 5 3.3 6,000 13.8 0 1.26 47.4 24.4 235.4 328 2403 41 20 6 0 0 0 0 5 31.05.2014 31.05.2014
31 B31 30 0 7 0 10 18.5 13,000 58.6 13.4 5.42 112.3 26.6 79.2 920 3600 14 17 4 0 0 0 0 1 12.05.2014 23.05.2014
32 B32 40 0 10 0 3 8.7 74,000 13.4 11.5 1.22 42.4 28.6 608.8 303 102 69 64 3 6 8 8 6 1 22.05.2014 17.06.2014
33 B33 36 0 15 0 3 5.4 45,000 16.7 11.6 1.52 44.1 29.2 78.1 237 183 60 47 3 8 8 0 12 4 12.06.2014 15.06.2014
34 B34 22 0 10 0 11 10.6 39,000 14.1 11.5 1.29 28.9 0 96.9 230 210 60 46 4 3 0 6 0 2 12.06.2014 25.06.2014
35 B35 28 1 10 0 11 4.9 61,000 28.7 13.7 2.63 76.7 32.4 52.9 367 213 62 43 2 8 8 6 20 2 14.03.2014 15.03.2014
36 B36 47 0 2 0 8 14.9 2,05,000 17.5 12 1.6 34.3 0 287.7 342 103 69 64 2 1 0 0 0 1 02.06.2014 03.06.2014
37 B37 50 0 15 0 3 8.5 2,60,000 13.5 11.5 1.23 31.1 0 126.4 223 107 69 58 6 4 0 0 0 2 03.06.2014 11.06.2014
38 B38 34 0 17 3 3 8.1 1,33,000 18.7 12.5 1.71 42.3 30.3 82.2 255 195 58 46 7 2 4 4 18 1 23.06.2014 20.07.2014
39 B39 46 0 15 0 5 6.6 44,000 36.6 12.4 3.37 42.4 27.4 70.8 465 978 34 25 10 30 20 10 98 4 04.07.2014 06.07.2014
40 B40 26 1 12 0 11 9.2 1,76,000 15.2 12.4 1.39 37.2 31.8 75.7 310 253 49 46 5 2 4 0 6 2 26.06.2014 28.06.2014
41 B41 68 0 15 4 9 5.7 43,000 14 11.5 1.28 46.5 34.7 142.5 276 246 53 41 9 3 6 4 6 1 03.07.2014 23.07.2014
42 B42 69 0 9 4 10 5.6 16,000 15.7 11.7 1.41 32.2 0 360.4 661 422 41 39 2 6 10 4 0 1 02.06.2014 18.06.2014
43 B43 62 1 10 4 3 11..9 51,000 16.6 12.5 1.52 48.2 29.1 94.9 282 142 64 53 3 4 6 0 12 1 06.05.2014 29.05.2014
44 B44 22 1 12 0 11 5.9 49,000 20.2 12 1.79 71.4 32.5 77.1 413 373 38 42 2 7 33 23 32 4 19.07.2014 22.07.2014
45 B45 19 1 15 4 3 8.6 83,000 18.9 11.4 1.73 31.4 0 371.9 199 144 63 53 14 5 0 0 0 3 08.07.2014 09.07.2014
46 B46 46 0 15 0 3 5.3 1,00,000 17.2 11.7 1.57 45.6 32.5 62.7 234 195 58 44 13 9 2 12 20 5 17.06.2014 20.06.2014
47 B47 29 1 16 0 8 8.3 6000 14.4 10.4 1.31 34.5 0 118.1 684 218 32 9 11 8 12 0 12 4 17.06.2014 18.06.2014
48 B48 55 0 10 0 3 8.7 50,000 24.8 13.4 2.27 39.7 32.5 311 343 226 51 55 1 3 4 0 0 5 30.06.2014 05.07.2014
49 B49 29 1 12 0 11 5.5 41,000 19.3 11.3 1.72 38 29.4 28.9 456 771 26 31 1 4 10 4 6 2 20.07.2014 25.07.2014
50 B50 73 0 8 0 10 14.3 2,63,000 24.6 12.2 2.25 56.3 35.1 238 1023 719 21 41 1 0 0 0 0 4 30.06.2014 01.07.2014
51 B51 28 1 15 0 3 8.3 1,46,000 14.4 11.3 1.3 30.8 0 403.7 245 122 66 56 14 2 0 0 0 1 22.07.2014 02.08.2014
52 B52 64 0 10 3 3 8.1 3,77,000 14.5 11.4 1.32 47.7 27.6 115 202 79 74 64 1 4 0 4 0 3 04.06.2014 20.06.2014
53 B53 56 0 15 0 3 9.2 66,000 13.7 10.9 1.25 40.4 29.6 344.3 394 186 44 9 1 11 8 4 24 3 04.06.2014 12.07.2014
54 B54 55 0 10 0 1 6.8 40,000 19.2 12.6 1.71 54.5 33.3 112.9 325 439 41 35 3 4 23 12 24 1 09.10.2013 26.10.2013
55 B55 28 0 10 0 3 9.6 48,000 17.2 12.4 1.52 56 30.2 114 356 336 60 28 5 2 8 0 0 5 03.06.2013 06.06.2013
56 B56 56 0 10 3 1 7.6 57,000 19.3 12.2 1.7 55.9 31.6 79.2 341 172 59 51 2 0 0 0 16 1 16.01.2014 03.02.2014
57 B57 58 0 10 3 1 5.9 1,00,000 27.2 12.9 2.34 79.2 30.8 43 225 271 50 42 2 3 4 0 4 1 24.11.2013 23.12.2013
58 B58 40 0 16 0 5 9.6 6,000 13.6 12 1.24 25 0 125.1 1708 423 32 26 5 0 0 0 0 5 30.05.2014 30.05.2014
59 B59 36 1 10 0 3 12.4 1,78,000 14.5 11.4 1.32 28.5 0 99.5 189 148 64 52 6 4 0 0 0 2 12.06.2014 28.06.2014
60 B60 35 1 24 0 13 8 13,000 17.5 11.4 1.6 42.9 31.2 446 520 708 38 30 2 2 8 4 0 4 10.07.2014 12.07.2014
61 B61 20 0 15 0 12 12.2 38,000 15.1 11.3 1.36 99.9 34.6 88.6 845 726 20 18 3 2 3 2 12 2 11.08.2014 12.08.2014
62 B62 38 0 15 0 3 7.2 1,33,000 18.4 12.6 1.64 40.2 32.8 183.9 318 85 73 62 3 6 10 8 12 1 05.08.2014 21.08.2014
63 B63 19 0 15 0 12 12.7 1,44,000 18.4 11.4 1.64 56.3 34.1 159.3 1078 745 23 29 2 2 0 0 0 4 02.08.2014 05.08.2014
64 B64 25 0 6 0 10 14.1 1,29,000 120 12.7 10 175 26.2 0 421 1251 30 24 2 2 0 0 0 4 30.07.2014 03.08.2014
65 B65 18 0 24 0 12 13 13,000 12.6 0 1.17 54.7 36.8 176 650 793 29 28 3 2 4 4 0 2 30.07.2014 05.08.2014
66 B66 55 1 15 0 12 7.2 138000 15.7 12.6 1.41 40.3 30.3 212 406 90 72 58 10 4 2 6 0 4 30.07.2014 17.08.2014
67 B67 73 0 10 4 3 5.1 3,02,000 13.5 11.3 1.22 49.1 28.6 222.1 269 70 76 70 3 2 0 0 0 4 25.07.2014 25.07.2014
68 B68 18 1 13 0 11 12.3 63,000 11.9 0 1.08 40 28.9 154.5 265 200 58 45 9 2 0 3 0 2 12.07.2014 25.07.2014
69 B69 57 0 10 1 10 7.4 106000 14.7 11.2 1.32 37.2 28.3 141.2 169 85 73 55 3 2 0 8 12 1 23.08.2014 30.08.2014
70 B70 21 1 10 0 11 3.8 30000 15.5 11.9 1.39 44.2 22.4 148.9 291 343 42 39 4 9 24 12 30 1 30.08.2014 01.09.2014
SL NO UIN AGE GENDER BLEEDING  DISORDER MEDICATIONS DIAGNOSIS Hb Platelet Count PT INR APTT FIBRINOGEN CT CFT alpha angle MCF ML
1 A01 65 1 2 0 0 13.4 5,27,000 10.9 1 28.1 358.3 251 52 79 72 10
2 A02 30 1 3 0 0 11.5 3,13,000 12.4 1.13 31.3 229.5 286 84 73 61 18
3 A03 28 1 2 0 0 13.3 1,96,000 11.9 1.09 26.1 244.6 311 87 73 64 17
4 A04 29 1 0 0 0 15.3 2,55,000 109 1 29.3 351.7 308 96 74 58 18
5 A05 36 1 1 0 0 14.2 2,29,000 12 1.1 29.8 392.3 446 136 64 61 17
6 A06 33 1 1 0 0 13.8 2,76,000 11.4 1.04 32.7 365.1 287 72 75 68 14
7 A07 76 0 8 0 0 10.8 1,16,000 11.8 1.08 27.9 385.2 265 75 75 66 13
8 A08 51 1 1 0 0 12.5 1,83,000 10.3 0.95 27.9 467.8 132 150 75 66 10
9 A09 28 1 11 0 0 13.5 2,31,000 10.8 0.99 33.4 311.4 239 79 74 64 18
10 A10 18 0 5 0 0 14.7 3,85,000 11.4 1.07 29.1 230.1 251 80 79 65 14
11 A11 61 0 8 0 0 10.9 1,05,000 10.7 0.97 31.7 339.2 559 126 66 67 7
12 A12 18 0 0 0 0 14 2,04,000 11.4 1.04 29.5 196.5 276 110 68 62 14
13 A13 42 1 11 0 0 10.5 1,38,000 10.5 0.96 27.7 428 284 81 76 74 7
14 A14 29 1 1 0 0 8.7 1,30,000 10.9 1 30.2 220.9 327 82 74 63 7
15 A15 22 1 11 0 0 12.5 1,76,000 10.9 1 26.3 267.6 382 123 67 65 2
16 A16 59 0 0 0 0 8.5 1,65,000 12.3 1.12 28.3 349.1 302 98 71 67 9
17 A17 21 0 0 0 0 16.6 2,13,000 11.5 1.04 33.4 180 325 138 65 55 9
18 A18 30 0 10 0 0 15.3 1,73,000 11.4 1.04 29.3 177.8 383 194 55 51 2
19 A19 20 1 5 0 0 6.8 5,08,000 11.9 1.09 29.2 492.7 279 70 79 83 6
20 A20 24 1 4 0 0 10.9 2,80,000 11.4 0.99 34.7 180 309 87 74 65 15
21 A21 18 1 11 0 0 12.8 2,50,000 10.7 0.98 34.2 301.9 365 89 73 65 6
22 A22 28 0 2 0 0 14.1 3,90,000 11.5 1.05 30.2 356.9 382 112 68 61 8
23 A23 25 1 0 0 0 12.9 2,44,000 11.1 1.02 30.4 317.4 372 126 65 60 10
24 A24 30 1 11 0 0 13.9 2,26,000 11.4 1.04 30.4 327 245 92 72 60 16
25 A25 53 1 10 0 0 12.9 1,84,000 10.1 0.93 25 377.9 267 88 74 63 13
26 A26 38 1 13 0 0 8.6 1,48,000 11.8 1.08 30 288.2 316 114 68 66 0
27 A27 53 0 2 0 0 13.9 1,05,000 10.7 0.98 35.3 365 198 181 65 73 4
28 A28 24 1 11 0 0 10 2,94,000 12.5 1.14 33 402 126 65 65 65 3
29 A29 65 0 3 0 0 13.5 2,59,000 11.2 1.03 30.6 320.2 350 178 60 52 5
30 A30 35 0 1 0 0 16.5 1,32,000 10.7 0.98 33.3 248 292 118 67 64 3
31 A31 47 0 11 0 0 10.7 3,12,000 10.8 0.99 31.7 295.3 294 90 74 68 11
32 A32 27 0 11 0 0 10.5 2,00,000 10 0.97 24 450.4 287 73 76 71 2
33 A33 25 1 3 0 0 8.4 1,51,000 10.5 0.97 29.1 492.3 319 100 73 77 6
34 A34 31 1 3 0 0 9.7 2,14,000 10.3 0.95 24 435.3 319 96 72 70 11
35 A35 24 0 10 0 0 10.8 2,78,000 11.5 1.05 29.8 156 479 104 73 75 7
36 A36 40 0 10 0 0 11.8 1,60,000 11.2 1.03 25 242 264 269 51 60 4
37 A37 47 0 0 0 0 10.5 2,51,000 12.5 1.14 30.3 332.1 442 94 71 65 11
38 A38 37 1 3 0 0 12.1 294000 11.5 1.05 31.1 404.5 367 96 72 68 9
39 A39 39 1 11 0 0 8.9 1,18,000 11.7 1.07 29.7 205.7 626 275 57 59 0
40 A40 53 0 0 0 0 13.4 2,74,000 11.2 1.03 30.4 476.9 302 76 76 74 9
41 A41 29 1 15 0 0 10.6 2,40,000 11.3 1.03 28.5 273.2 260 101 70 63 10
42 A42 23 1 11 0 0 12.6 3,55,000 10.7 0.98 36.6 273.2 355 82 73 68 10
43 A43 22 1 11 0 0 11.2 2,90,000 10.9 0.99 32.6 234.1 341 95 71 65 3
44 A44 22 0 0 0 0 13.7 2,02,000 11.1 1.01 33.6 155.9 432 150 62 59 2
45 A45 25 0 2 0 0 15.5 2,57,000 10.3 0.95 33.5 281.4 396 169 59 61 3
46 A46 32 1 2 0 0 13.1 2,77,000 10.9 0.99 35 371.5 354 82 74 69 9
47 A47 36 0 10 0 0 14.6 2,00,000 10.9 0.99 32.5 243.9 370 107 70 68 5
48 A48 25 1 15 0 0 13.4 2,87,000 10.8 0.98 29 303.4 341 82 74 68 7
49 A49 30 0 7 0 0 14 1,58,000 11.4 1.03 32.2 247.3 347 103 70 65 6
50 A50 31 0 11 0 0 12 1,75,00 10.5 0.95 25.3 215.9 400 138 64 60 12
51 A51 31 0 0 0 0 12.9 2,02,000 11.2 1.02 33.5 222.9 630 167 59 55 11
52 A52 45 1 1 0 0 11.6 2,38,000 9.8 0.89 32.3 211.5 271 81 75 72 8
53 A53 24 1 2 0 0 11.7 2,99,000 11.4 1.04 26 184.2 416 130 65 65 3
54 A54 38 0 0 0 0 22.9 1,05,000 12.2 1.11 31.5 240.7 1093 523 28 38 2
55 A55 67 1 10 0 0 13.2 2,28,000 11 1 27.6 227.8 189 79 74 63 10
56 A56 24 0 15 0 0 14.6 2,57,000 12.4 1.12 36.3 598 736 163 62 68 8
57 A57 23 0 0 0 0 14.8 1,60,000 11.4 1.03 33.5 180.2 589 191 56 54 5
58 A58 30 0 0 0 0 9.7 3,77,000 11.4 1.04 27.3 284.1 321 76 75 69 9
59 A59 30 1 15 0 0 8.2 3,33,000 11 1 30.1 608.9 266 55 79 75 7
60 A60 41 0 0 0 0 15.3 2,70,000 10.5 0.95 30.2 287.7 404 121 68 67 5
61 A61 19 1 11 0 0 10.6 2,40,000 10.5 0.95 29.2 243.4 389 124 65 66 6
62 A62 18 1 11 0 0 12.2 3,19,000 10.9 0.99 33.1 280.6 387 129 66 63 5
63 A63 19 0 5 0 0 14 3,07,000 10.8 0.98 27.7 251.9 321 94 71 66 8
64 A64 25 1 11 0 0 12 1,05,000 11.4 1.04 29.8 320 285 96 71 65 11
65 A65 37 0 2 0 0 7.4 1,66,000 11.8 1.07 32.5 180.7 295 124 66 55 8
66 A66 18 1 8 0 0 11.2 4,97,000 11.1 1.01 30.4 296 260 68 77 73 8
67 A67 20 0 0 0 0 15.7 2,55,000 11.4 1.04 29.1 191.4 379 131 64 53 11
68 A68 19 1 11 0 0 9.6 2,52,000 11.4 1.03 28.5 167.3 409 125 65 60 9
  
 
GENDER BLEEDING  DISORDER MEDICATIONS DIAGNOSIS
0-Male 0- No bleed 0- Nil 0- NORMAL
1-Female 1- Skin bleeds 1- Antiplatelet 1- ORTHOPTIC  LIVER TRANSPLANATION
2- Epistaxis 2- VKA 2- VIT K DEPENDANT FACTOR DEFICIENCY
3- Gum bleed 3- Heparin 3- TRAUMA INDUCED COAGULOPATHY
4-  tooth extraction bleeds 4- 1 and 3 4- ACQUIRED F VIII DEF
5- prolonged bleeds 5- MALIGNANCY ASSOCIATED COAGULOPATHY
6-haematemesis 6- LUPUS ANTICOAGULANT
7- Hematochezia 7- SUB ACUTE DIC
8- Hematuria 8- FACTOR DEFICENCY
9-Malena 9- SEPSIS RELATED COAGULOPATHY
10-Intra op bleed 10- COAGULOPATHY ASSOCIATED WITH LIVER DISEASE
11- Menorrhagia 11- COAGULOPATHY ASSOCIATED WITH OBSTETRIC CASES
12- PPH 12- SEPSIS ASSOCIATED COAGULOPATHY
13-Haematuria 13- COAGULOPATHY ASSOCIATED WITH SNAKE BITE
14- Haemarthrosis
15-Others
16- IC/SD BLEED
17- traumatic bleeds
18-intra op+ others
19-Hematuria + malena
20- skin bleed + gum bleed
21- epistaxis + gumbleed
22-malena + gumbleed
23- gum bleed + menorrhagia
24 - multiple bleeds
